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Primary immunodeficiencies (PIDs) are rare and several genetic defects that influence the development 
function of immunity [1]. Immunodeficiency disorders include both the hematopoietic and non-
hematopoietic arms of host defense. The hematopoietic arms include all the immune system cells derived 
from the hematopoiesis process and from the subsequent differentiation (such as lymphocytes, monocytes, 
NK cells, dendritic cells or macrophages) as well as the mediators produced by these cells (such as antibodies, 
cytokines or enzymes). The non-hematopoietic arms include passive defenses, such as anatomical barriers 
and pathways, exogenous body secretions, physicochemical environments, ciliary activity or microbiological 
flora, and active defenses such as physiological responses (elevated body temperatures, tachycardia, 
vomiting and diarrhea), formation of nitric oxide from arginine and acute-phase reactions. The defects of 
these host arms defense resulting in a wide spectrum of clinical symptoms, including susceptibility to 
infections, autoimmunity, inflammation, allergy, and increased incidence of malignancy. PIDs confer 
predisposition to multiple clinical and immunological phenotypes and an increasing number of PIDs are being 
shown to confer predisposition to a single type of infection [1]. Despite most humans carry genetic errors of 
immunity, PIDs are typically rare and classified with familial recessive or dominant tracts. The presence of 
mutations in patients’ genome may be due to the inheritance of mutations with complete or incomplete 
penetrance from an affected parent, de novo dominant lesions in the germ line or somatic mutations.  
 
1.1  COMMON VARIABLE IMMUNODEFICIENCY DEFICIENCY (CVID) 
In 1971 World Health Organization coined the term “Common Variable Immunodeficiency” (CVID) to 
describe a number of poorly defined immunodeficiencies characterized by antibody deficiency without a 
clear Mendelian inheritance [2,3]. Currently, the International Union of Immunological Societies Expert 
Primary Immunodeficiency Committee refer to CVID as “common variable immunodeficiency disorders”, 
focusing attention to the heterogeneous nature of the disease [4] and the European Society for 
Immunodeficiencies and the Pan American Group for Immunodeficiency defined CVID as probable in a male 
or female patient who has marked decrease of IgG (at least 2 SD below the mean age) and a marked decrease 
in at least one of the isotypes IgM or IgA, and fulfills all of the following criteria (summarized in Table 1) : 
1. Onset of immunodeficiency at greater than 2 years of age 




3. Defined causes of hypogammaglobulinemia have been excluded according to a list of differential 














Clinical criteria for a probable diagnosis (= clinical diagnosis) Suggestions for alternative diagnosis (i.e. 
if these criteria are not completely 
fulfilled) 
At least one of the following: 
- increased susceptibility to infection 
- autoimmune manifestations 
- granulomatous disease 
- unexplained polyclonal lymphoproliferation 
- affected family member with antibody deficiency 
AND marked decrease of IgG and marked decrease of IgA with or without low IgM levels 
(measured at least twice; <2SD of the normal levels for their age); 
AND at least one of the following: 
-  poor antibody response to vaccines (and/or absent isohaemagglutinins); i.e. absence 
of protective levels despite vaccination where defined 
- low switched memory B cells (<70% of age-related normal value) 
AND secondary causes of hypogammaglobulinaemia have been excluded (see 
Table 2) 
AND diagnosis is established after the 4th year of life (but symptoms may be present 
before)  
AND no evidence of profound T-cell deficiency, defined as 2 out of the following (y=year 
of life): 
- CD4 numbers/microliter: 2-6y <300, 6-12y <250, >12y <200 
- % naive CD4: 2-6y <25%, 6-16y <20%, >16y <10% 
- T cell proliferation absent 
For patients <4 years old or patients with 




For patients with evidence of profound T-cell 
deficiency, please consider Unclassified 
combined immunodeficiencies. 
Table 2. Differential diagnosis of CVID 




As result of this classification, CVID can be considered as a group of heterogeneous primary antibody failure 
syndromes characterized by hypogammaglobulinemia [5, 6]. The lack of an efficient antibody production is 
the result of a B cell dysfunction or a of T cell function impairment with consequently lack of help for antibody 
production. A lower limit value of IgG at 4.5 g/L for adults has been proposed considering that nearly 95% of 
CVID patients in a European cohort fulfilled this criterion [7] although some patients present high residual 
IgG levels (up to 6 g/L) at diagnosis while still showing impaired specific antibody formation [8]. In addition, 
the level of IgG might vary depending from ethnicity and therefore the definition of hypogammaglobulinemia 
depends from the region considered [9].  
 
1.2 DEFINITION OF CVID 
The criteria used [10] for the diagnosis of CVID are: 
1. At least one of the characteristic clinical manifestations (infection, autoimmunity, 
lymphoproliferation). 
2. Low level of IgG must be observed at least 2 times, more than 3 weeks apart and the diagnosis of 
hypogammaglobulinemia should be defined considering the age-adjusted reference range. If the IgG 
level is very low (<100-300 mg/dL depending on age) and other characteristic features are present, 
repeated measurement can be omitted.  
3. Low level of IgA or IgM  
4. If the IgG level is more than 100 mg/dL must also present an impairment of response to T-
dependent (TD) and/or T-independent (TI) antigens 
5. Other causes of hypogammaglobulinemias must be excluded (Table 2). 
6. Genetic studies are generally not required; anyway, the genetic characterization may be useful to 
set specific therapies (as stem cell therapy).  
 
1.3 EPIDEMIOLOGY OF CVID 
CVID is the most frequent symptomatic antibody deficiency diagnosed in adulthood [11,12]. Although IgA 
deficiency occurs with an overall higher frequency, most patients with IgA deficiency are asymptomatic [13]. 
There are no precise data on the prevalence of CVID, but it was estimated to be between 1: 100.000 and 1: 




different methodologies of study, access to health care, rate at which patients are properly diagnosed or 
population genetic differences [7]. 
 
1.4 PATHOGENESIS OF CVID 
In 98% of cases, the genetic defects responsible for CVID patients’ condition are unknown. The fundamental 
characteristics found in all CVID patients is a condition of hypogammaglobulinemia associated with loss of B 
cell function.  The loss of B cell function may be due to an intrinsic defect of B-lymphocytes or T- lymphocytes 
that do not provide a sufficient support to B-lymphocytes. In the majority of cases, there is a decrease of 
isotype-switched memory B cells [14,15] and a loss of plasma cells in both bone marrow and mucosal tissues 
[16,17]. 
Although B cells in vitro are usually able to produce normal amounts of immunoglobulin, in others cases B 
cells produce only IgM or they are unable to produce immunoglobulin at all [18]. 
One recent [19] analysis seem distinguished five possible subgroups or defects:  
1) B cell production  
2) early peripheral B cell maturation or survival  
3) B cell activation and proliferation  
4) germinal center 
5) post-germinal center  
Interestingly some patients present an impaired calcium flux after activation of the B cell receptor and an 
expansion of the CD21-low B cell population. In some patients, it was described also a T cell loss of function, 
including a reduction of circulating CD4 T cells and impaired proliferation, activation, and secretion of some 
cytokines (IL-2, IFN-g, and IL-10) with increases of IL-6 and perhaps IL-12 [20-25]. More recently, defects in 
monocyte/dendritic and impaired innate immune responses have also been demonstrated. [26,27] 
 
1.5 CLINICAL MANIFESTATIONS 
The onset of symptoms appears usually during the first and the third decade of life with a slightly bimodal 
onset [28,29]. At the time of diagnosis, severe infections are common and complications related to immune 
dysregulation are present in approximately 20-30% of patients. Up to 80% patients have infection-related 
structural changes such as bronchiectasis [20,30,31]. CVID patients develop various additional clinical 




gastrointestinal inflammatory disease, lymphoid hyperplasia and/or cancer or lymphoma, each of these with 
a different prevalence depending on the country considered [10]. Chronic lung disease is the leading cause 
of mortality in CVID [28,30,32]. Granulomatous disease or atypical sarcoid-like lesions commonly affect 
lungs, lymph nodes, and spleen (8%-22% of CVID patients). However, skin, liver, bone marrow, kidney, 
gastrointestinal tract, eyes, and/or brain may also be involved [35-38].  
Autoimmunity occurs in 25%-30% of CVID patients [28, 31] and in about 3-5% of CVID patients autoimmunity 
was the only clinical complication at the time of diagnosis [39]. Thus, CVID patients might display 
autoimmune manifestations before the appearance of hypogammaglobulinemia, similar to those patients 
with syndromes of immune dysregulation such as autoimmune lymphoproliferative syndrome [40]. The most 
common autoimmune diseases include immune thrombocytopenia purpura (ITP) and autoimmune 
hemolytic anemia (AIHA), while autoimmune neutropenia is much less common [41-43].  
Recently, different forms of enteropathy were found in 10-20% of CVID [28] with a high rate of nonmalignant 
mortality, possibly due to malabsorption [29,44]. Bacterial, protozoal and viral gastrointestinal infections 
occur in CVID as well as small bowel inflammation. Bowel inflammation is also associated with unexplained 
persistent chronic diarrhea, weight loss, steatorrhea, and malabsorption with loss of both minerals and fat-
soluble vitamins [45–47]. Typically, bowel mucosa shows common histological feature in CVID like villous 
blunting and crypt distortion with increased lymphocytes (usually CD8 T cells), lymphoid aggregates 
(lymphoid hyperplasia), and loss of plasma cells [45,48]. Also liver abnormalities, mainly due to nodular 
regenerative hyperplasia, are common in CVID, in particular hepatomegaly and increased levels of liver 
enzyme, including alkaline phosphatase [49–51].  
At least 20% of CVID present cervical, mediastinal, and abdominal lymphoid hyperplasia and/or 
splenomegaly [52,53]. Lymph nodes usually show atypical lymphoid hyperplasia, reactive lymphoid 
hyperplasia, or granulomatous inflammation and these tissues need to be examined for B- and T cell 
clonality. However, the presence of clonal lymphocytes is not diagnostic of lymphoma because these can be 
found in CVID lymphoid tissue showing reactive hyperplasia (53). Finally, CVID patients display an increased 
incidence of cancer compared with the general population, occurring in about 20% of patients and 







1.6 LABORATORY MANIFESTATIONS 
One of the main characteristics shared by all CVID patients is a low level of different classes of serum 
immunoglobulin, in particular a level of IgG less than 4.5 g/L (85%-94% of patients) while IgM levels are 
variable. Different studies suggest a level between 0.25g/L and 0.4g/L although one study shows that females 
patients tended to have higher levels. IgA levels are typically low or undetectable in CVID, with 70% of the 
patients showing values of less than 0.1 g/L [29,44,54,55].  About 20% of the patients with CVID may have 
very low levels or absence of all immunoglobulin isotypes at presentation [15,28]. Specific antibody 
production may be variable in some patients with CVID and it might decrease over time [56]. 
Most patients with CVID will have normal levels of total circulating T cells and natural killer (NK) cells in 
peripheral blood [29,57]. The number of B cells is normal in the vast majority of CVID, about 10% had an 
increased level and about 10% of patients had reduced or undetectable levels [55].  
CVID patients might also display variable dysfunction within the T cell compartment [58]. One study showed 
that CD4 T cells were decreased in 29% of CVID patients, while 50% of this cohort demonstrated abnormal 
proliferative responses to mitogens [44]. Others studies showed restricted T cell receptor repertoires, 
oligoclonality, increased T cell apoptosis, and reduced expression of CD40L [59–61].  
It was shown that also dendritic cells and regulatory T cells may contribute to the pathogenesis of CVID, even 
if their role are yet to be fully elucidated [23,62,63]. 
 
1.7 GENETICS 
Most CVID cases are sporadic and approximately 5-25% of cases are familial, typically with an autosomal 
dominant inheritance [64, 65]. Different studies point their attention to the HLA region on chromosome 6p 
and different HLA-DQ/DR haplotypes could confer either protection or susceptibility to CVID [66]. A genetic 
linkage study showed mutations on chromosome 4q and 16q associated with CVID, although the mutated 
genes have not been identified [29,67]. Currently only 2% of CVID cases are explicable by a clear genetic 
mutation, many patients with these mutations exhibit combined immunodeficiency with clinical 
characteristics or laboratory abnormalities not commonly seen in CVID, therefore, these disorders are 
classified as distinct entities on the basis of the defined genetic defects [68] 
It was observed that particular polymorphisms of TACI and MSH5 genes are associated with CVID although 
these same polymorphisms are present in about 1% of healthy individuals [68, 69]. However, the variable 




1.8 IMMUNOGLOBULIN REPLACEMENT THERAPY 
Currently the standard therapy for CVID is the IgG replacement that can be given by intravenous (IVIg) or 
subcutaneous (SCIg) route at varying intervals [70]. Most guidelines suggest to start with a dose of 0.4 to 0.5 
g/kg/month for IVIg and 0.4 to 0.6 g/kg/month for SCIg [71]. Higher doses are proposed in case of 
complications such bronchiectasis, splenomegaly and enteropathy [30,72-74]. IVIg infusions are usually 
given every 3- or 4-week and typically adverse reactions, such as headaches, nausea and vomiting, flushing, 
hives, chills, myalgia, arthralgia, or abdominal and/or back pain are reduced slowing the infusion rate.  
Although complications due to transmission of infectious agents, such as hepatitis B or hepatitis C, are 
extremely rare [75] it is important to monitor patients on replacement therapy for transmission of unknown 
or new pathogenic agents. Finally, renal complications can occur patients receiving IVIG and are associated 
with sucrose-containing products and in patients with preexisting kidney disease [76].  
 
1.9 X-LINKED AGAMMAGLOBULINEMIA  
X-linked agammaglobulinemia (XLA) was one of the first immunodeficiencies described with distinctive 
clinical and laboratory findings. The first symptoms typically appear in the first 24 months of life and include 
profound hypogammaglobulinemia and strongly reduced numbers of B cells. The genetic defect, that occur 
with a frequency of about 3-6/million, was found on X chromosome, in the locus that encode a cytoplasmic 
tyrosine kinase called BTK [77,78].  
 
1.10 CLINICAL FINDINGS IN XLA 
XLA patients generally do not present any symptoms during the newborn period due to the maternal 
immunoglobulin acquired transplacentally. In patients with XLA who have no family history of 
immunodeficiency the mean age at diagnosis is 2-3 years old [79,80].  Recurrent bacterial infections, 
particularly otitis, purulent rhinorrhea, conjunctivitis, pneumonitis, diarrhea, and skin infections typically 
appear in the second half of the first year of life [79,81, 82,83].  Haemophilus influenzae and Streptococcus 
pneumoniae infections are common. In addition, XLA patients are susceptible to infection with Mycoplasmas 
and Ureoplasmas that may cause persistent pneumonia, arthritis, cystitis, or cellulitis [84,85]. XLA patients 
are particularly susceptible to chronic enteroviral infections, including vaccine-associated polio while do not 





1.11 LABORATORY MANIFESTATIONS 
XLA patients show markedly decreased numbers of B cells (0.1% of circulating lymphocytes) and a low 
concentration of all isotypes of serum immunoglobulins [89]. The IgG are usually less than 200 mg/dL, and 
the IgM and IgA less than 20 mg/dL. Genetic studies showed that the mechanism of rearrangement of 
immunoglobulins genes was preserved although there may be an over-representation of V, D, or J segments 
that are typical of a fetal repertoire [90-93]. A definitive diagnosis of XLA can be made if male 
agammaglobulinemic patients present a family history of hypogammaglobulinemia, <2% B cells, mutation in 
BTK or the absence of BTK protein or mRNA. Studies performed in bone-morrow show a defect during the 
development of B cells in the transition between the pro-B cells (CD34 + CD19+ sIg-) stage and pre-B cells 
(CD34-CD19+sIg-) [94].   
 Generally, 20-25% of patients show neutropenia at the time of diagnosis that can persist for several weeks 
after IVIg therapy started [79,80], in addition XLA patients might have an increased percentage of monocytes 
[95]. 
 
1.12 THE DEFECTIVE GENE: BTK 
Bruton’s tyrosine kinase (BTK) is a member of a family of cytoplasmic tyrosine kinases, called Tec kinases 
[96,97]. BTK is predominantly expressed in B cell lineage (except in terminally differentiated plasma cell 
stage), but it is also expressed in myeloid cells [98]. BTK is a member of a family of Src-related cytoplasmic 
tyrosine kinases that includes Tec, Itk, Rlk, and Bm, that participate in signal-transduction pathways involving 
growth or differentiation factors [99]. Members of Src-related kinases are characterized by a C-terminal 
kinase domain preceded by SH2 and SH3 domains, a proline rich tract and an NH2-terminal PH (pleckstrin 
homology) domain. Typically, SH3 domains bind proline-rich regions and SH2 domains bind phosphorylated 
tyrosine residues [100] while the PH domain brings BTK to the inner side of the plasma membrane by binding 
phosphorylated phosphatidyl inositides produced in response to cellular activation [101]. The PH domain is 
also able to bind the protein kinase C (PKC) and both the α and β/γ subunits of G proteins [102-104]. The 
proline rich tract that follow the PH region of BTK it was been reported to interact with the SH3 of the Src 




Several studies showed that BTK is activated through a variety of cell surface molecules, in particular the BCR 
and pre-BCR [106–108] but also others such as IL-5 and IL-6 receptors on B cells [109, 110], the high affinity 
IgE receptor on mast cells [111]. More recently, a study performed by Ren et al [112] showed the importance 
of BTK in those pathways activated by FcγR pathway in innate immune cells such monocytes/macrophage 
system.  
As shown in Figure 1, upon cell activation BTK moves to the inner side of the plasma membrane, where it is 
phosphorylated and partially activated by a Src family member [113], then BTK undergoes 
autophosphorylation [114]. Activated BTK and PLCγ2 bind the scaffold protein BLNK via their SH2 domains, 
inducing BTK to phosphorylate and activate PLCγ2 [115]. This leads to the production of IP3 that induce the 
calcium mobilization from the internal storage trough the binding of IP3 with its receptors (IP3R) present on 
the endoplasmic reticulum. The calcium mobilization results in the activation of the MAP kinases ERK and 
JNK [116] and others cellular processes such activation of PKC [117]. In addition, BTK phosphorylates several 






Figure 1. Signal transduction through the pre-B 
cell receptor [98]. After activation, Syk 
phosphorylates multiple tyrosine residues in 
the scaffold protein BLNK. Lyn also 
phosphorylates BTK and CD19. 
Phosphatidylinositol 3-kinase (PI3K) bind CD19 
and produces PIP3 that work as  as a docking 
site for BTK and PLCγ2. BTK and PLCγ2 bind to 
phosphorylated tyrosines in BLNK, which 




1.13 DIFFERENTIAL DIAGNOSIS 
Male and female patients are equally affected by the non-X linked forms of B cells deficiency, [88,120,121] 
and several defects in B cells lineage are difficult to distinguish from XLA (Table 3). Mutations in mu heavy 
chain result in a clinical picture similar to that observed in XLA but generally these patients show a more 
severe phenotype have an earlier onset of symptoms and more severe infectious complications than patients 
with XLA. Patients with defects in mu heavy chain demonstrate a complete absence of B cells in the 
peripheral circulation that result in <0.01% of peripheral blood lymphocytes [122] while XLA patients show 
generally markedly reduced but detectable numbers of B-Cells [89,123]. Moreover, also the concentrations 
of serum IgG are lower in patients with mutations in mu heavy chain compared to XLA.  
 
These observations suggest a beneficial effect of the residual amount of immunoglobulin present in XLA 
patient, possibly due to Fc receptor-binding function or to antigen binding properties.  
In addition, mutations in λ5/14.1, a component of the surrogate light chain, are responsible for the block of 
B-cell differentiation at the pro-B cell stage [124]. Patients with mutations in λ5/14.1 display profound 
hypogammaglobulinemia and reduced B cells but unlike in XLA, B cells show a mature phenotype [124]. 
 
1.14 IMMUNOGLOBULIN REPLACEMENT THERAPY  
IVIg replacement is the standard therapy for patients with XLA. Generally, IVIg are given at a dose of 400 
mg/kg every 3/4 weeks [125]. Also SCIg can be a choice for the treatment of XLA, in this case patients can 
self-administer the Igs, dividing them in weekly doses. There is not a consensus about the use of prophylactic 
antibiotics in patients with XLA. 





1.15 MONOCYTES SUBSETS 
Monocytes were recently classified in three different subsets according to their expression of CD14, the 
receptor of LPS and CD16, a low affinity Fc receptor, in classical monocytes (CD14++CD16-), intermediate 
monocytes (CD14++, CD16+) and non-classical monocytes (CD14+ CD16++) (Figure 2) [126]. Therefore, this 
new segregation raises the possibility that specialized functions and phenotype can be attributed to these 
newly defined monocyte subsets. Our knowledge about the three monocytes subsets was recently improved 
by genome wide analyses [127-129]. The relationship between the different monocytes subsets it is not 
clear. A study by Cros et al. [127] reported that classical and intermediate monocytes were the most closely 
related among the subsets, although other studies showed that intermediate and non-classical subsets are 
more closely related [128, 129], since these two subsets display the highest the number of genes equally 
expressed between the three subsets [128] suggesting a direct development relationship between these two 
subsets.  
There is very poor agreement 
regarding the cytokines production 
by the three monocytes subsets.  In 
the study by Cros et al. [127], isolated 
non-classical monocytes were poor 
producers of several cytokines in 
response to LPS (including TNF-α, IL-
1β, CCL2, IL-10, IL-8, IL-6 and CCL3) 
but responded strongly to TLR7/8 
ligands while the intermediate subset 
treated with LPS produced the most 
TNF-α, IL-1β and IL-6. Also Rossol et 
al. [130] showed that the 
intermediate monocytes stimulated in vitro with LPS produced the most TNF-α and IL-1β as well as TNFα 
when co-cultured with pre-activated T cells, while Wong et al [128] showed that non-classical subset are the 
main producer of TNF-α and IL-1β in response to LPS while equivalent amounts of IL-6 and IL-8 were 
produced by all three subsets. The data are conflicting also regarding the anti-inflammatory cytokine 
production: Skrzecynska-Moncznik et al. [131] showed that the intermediate monocytes are the main 
Figure 2 Human monocytes subsets [121]. Classical and intermediate 
monocytes express by definition, the same level of CD14+ while non 





producers of IL-10 in response to LPS and zymosan but others [127,128,132] showed that classical 
monocytes were the main producers of IL-10.  The different isolation methods used to purify the monocyte 
subsets might be responsible for the differences in cytokine production reported by the different groups, 
anyway, the staining in whole blood condition is probably the most ideal in order to minimize nonspecific 
effects that may occur during isolation and in vitro culture [133].  
The intermediate monocyte subset expresses the higher levels of MHC class II processing and presentation 
genes as well surface molecules involved in antigen presenting to T cells, particularly CD40 and CD54 [128, 
129]. Indeed, in line with these observations, intermediate monocytes were shown to be the best inducers 
of SEB-mediated T cell proliferation and the best T cell stimulators with influenza type A antigen [129, 134], 
even if most of these assays were performed using experimental systems that bypass the antigen 
phagocytosis. Moreover, also classical monocytes could overexpress MHC class II making them capable to 
induce T-cell proliferation after activation with SEB [129]. Therefore, it is possible that in vivo also classical 
monocytes can induce T cell proliferation if properly activated as it could happen locally in inflamed tissues 
where activated monocytes migrate [135, 136]. Conversely the highest expression of MHC I was found in 
CD16+ monocytes, even if it is not clear if the maximum expression is on intermediate [128] or non-classical 
[129] subsets. Cros et al [127] observed that non-classical monocytes showed a typical patrolling behavior 
since they continuously roll on endothelium looking for signs of inflammation or damage in order to 
transmigrate rapidly. In support of this observation, genes associated with cytoskeleton mobility, such as 
Rho GTPases, RHOC and RHOF, and several upstream Rho activators and downstream effectors were most 
highly expressed by the non-classical subset [128, 129]. 
Interestingly, many infection or inflammatory conditions were associated with the expansion of the CD16+ 
monocytes [137–143].  CD16+ monocytes are often termed ‘‘pro-inflammatory’’ monocytes in line with their 
ability to produce high amounts of TNF-α and IL-1β [133, 144] and therefore they might play important roles 
in promoting inflammation. With the new subdivision of CD16+ monocytes in intermediate and non-classical 
subsets it is clear that it will be important to understand which population is expanded and to deduce their 
roles in diseases based on phenotypic and functional properties and also from the gene expression profiling 
studies. As reported by Wang et al [145] increasingly evidences appear to show that intermediate monocytes 
are the monocyte population that most often is expanded in inflammatory and infectious conditions.  
It was initially reported an expansion of CD16+ monocytes in sepsis [137] and recently it seems that 




positive association of both pro-inflammatory and anti-inflammatory cytokines with CD16+ monocytes [144, 
133,131, 137] but the exact source of these cytokines in vivo and the precise contribution of the intermediate 
and non-classical subsets remain unclear.  It was also reported an expansion of intermediate monocytes in 
tuberculosis (TB) [147],   
Castano et al. found an increased number of CD16+ monocytes with a more significant expansion of 
intermediate monocytes than the non-classical subset [138]. The ex-vivo characterization of monocytes 
subsets form patients with TB showed that the expression of many markers related to maturation, 
differentiation and function are similar to HD except for higher CD11b and lower HLADR in the non-classical 
subset of TB patients [138]. Probably CD11b is able to enhance intracellular survival of the M. tuberculosis 
[148], while low HLA-DR expression suggests reduced antigen processing and presentation capability of the 
expanded subset [149]. On the other hand, during the infection, the CD16+ monocytes produced more TNF-
α [138], which has been associated with the control of TB [150], even if it is not known which CD16 + subset 
is the main producer of TNF-α.   
 Also in several viral infections, such as HBV, HCV and HIV, it was reported an expansion of both non classical 
and intermediate monocytes [151–153]. This expansion is most likely detrimental for HIV patients in that 
CD16+ monocytes express higher level of CCR5 and CD4 [153-155] and therefore are more permissive to 
infection by HIV than the classical monocytes. Moreover, the number of intermediate monocytes correlates 
positively with the increased plasma viral load and decreased CD4+ T cells [153].  As a result of their greater 
permissiveness to HIV infection, it was strongly suggested that CD16+ monocytes may be acting as Trojan 
horses, playing an important role in viral dissemination [156, 157]. The increased number of CD16+ 
monocytes in HIV infection could be explained by their enhanced survival due to the fact that infected 
monocytes exhibit an anti-apoptotic gene signature [158]. Similarly to HIV, also HCV infect both intermediate 
and non-classical but not classical monocytes [159] probably due to the higher expression of CD81 in these 
two subsets compared to the classical monocytes [159]. In fact, CD81 has been reported previously as the 
primary receptor for HCV [160, 161]. Interestingly, monocytes infected with HCV seem facilitate HIV co-
infection and vice versa [159, 162], and the intermediate monocytes were the ones that exhibit coinfection 
by both HCV and HIV, indicating that they are capable of supporting replication of both viruses [159]. 
 Also in autoimmune disorders, such as rheumatoid arthritis (RA) [130, 141, 163, 164], Crohn’s disease (CD) 
[165–167], it was reported a perturbation in monocyte subsets composition. Several studies showed the 




increased. Some studies reported an expansion of non-classical monocytes [164] and others of the 
intermediate monocytes [130] In addition, which monocyte subset is the main producer of the pro-
inflammatory cytokine in RA patients is still an open question. Also in human inflammatory bowel disease 
(IBD) such as CD or ulcerative colitis (UC) it was observed an expansion of CD16+ monocytes [165, 166]. In 
particular, Grip et al [167] showed in CD an increased number of intermediate monocytes and it is possible 
that also in UC [166] the subset expanded is the intermediate monocytes. In addition to autoimmune disease, 
also numerous inflammatory diseases present increased CD16+ monocytes. Typically, several inflammatory 
diseases show an expansion of intermediate monocytes as in asthma, renal disease, stroke and hemodialysis 
[168-171], even if also non-classical monocytes can be increased as in the aseptic loosening of implants, 
coronary artery disease and periodontitis [172-174].  
 
1.16 POLYMORPHONUCLEAR LEUKOCYTES  
Polymorphonuclear neutrophils (PMN) are the most numerous cells of the innate immune system and play 
a key role in the first line of host defense against pathogenic organisms. PMN develop in the bone marrow 
from the myeloid hematopoietic system and share numerous characteristics with other myeloid cells such 
as monocytes [175].  PMN are short-lived, terminally differentiated cells and without an activating stimulus, 
such as inflammatory or infectious stimuli, survive only for a short time in the blood stream (5-90 hours) and 
then die spontaneously by apoptosis. During microbial infections, circulating microbial products and 
endogenous pro-inflammatory mediators favor PMN survival, a mechanism critical for their tissue 
accumulation and effectiveness against pathogens [176, 177]. In response to inflammatory stimuli, PMN 
migrate quickly from bloodstream to the infection site (24-48h lifespan), where they perform phagocytosis, 
granule exocytosis and the reactive oxygen species (ROS) production, also called oxidative burst. These 
processes are crucial for bacterial killing but might also cause tissue injury if excessive or inappropriate 
[175,178]. Neutrophils express a large number of cell surface receptors for the recognition of microbial 
invasion, capable to recognize microbial structures (such as TLRs or scavenger receptors). Other receptors 
(such as Fc-receptors) function as a link between innate immunity and the adaptive immunity, and yet other 
receptors recognize the inflammatory environment.  
A natural consequence of this variety of surface receptors is that in PMN exist a large number of 
interconnected intracellular pathways activated by surface receptor that can be involved directly in the 




indirectly required for the elimination of pathogens (such as chemotaxis). Taken together, intracellular signal 
transduction processes provide large amount of complex information to support an efficient antimicrobial 
immune response. Malfunctions and defects in PMN can play a significant role in various primary 
immunodeficiencies. Numerous PMN defects have been identified in PIDs such as chronic granulomatous 
disease (CGD) [179], warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome [180] and 
leukocyte adhesion deficiency syndromes (LAD) [181]. In particular, CGD patients display recurrent pyogenic 
infections and granulomatous inflammation caused by the loss of phagocyte superoxide production due to 
recessive mutations of the four genes encoding subunits of the phagocyte NADPH oxidase [179]. Mutations 
of CXCR4 are responsible for WHIM that is characterized by deficiency of circulating neutrophils and their 
accumulation in the bone marrow [180]. LAD syndromes are characterized by defects in adhesion process of 
PMN and monocytes that results in severe infectious such as omphalitis, pneumonia, gingivitis, and 
peritonitis and absence of abscess [181]. Neutropenia is also observed in patients with X-linked IgM 
syndrome (XHIGM), a rare immunodeficiency due to mutations of the gene encoding for CD40L on 
chromosome X, characterized by normal or elevated serum IgM, reduced levels of IgG, IgA and IgE and 
defective T cell functions [182]. However, the role of PMN in CVID and XLA has not been fully elucidated. 
Several abnormalities of innate immune system have been reported in CVID patients, such as defect in 
differentiation and maturation of dendritic cells (DC) [183, 184], reduced absolute numbers of NK cells [57] 
and also neutropenia [185]. However, phenotype and functions of PMNs in these patients have not been 
fully elucidated.  
In XLA, although BTK expression is abundant in neutrophils, patients under IVIg therapy are generally healthy 
[186,187], suggesting that BTK is dispensable outside the B cell compartment. In a recent study, it was 
demonstrated that TLRs activation in XLA neutrophils is able to induce a normal activation of ERK and JNK 
kinases and a respiratory burst comparable to that observed in normal controls, probably because other Tec 
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2. AIM OF THE STUDY  
Intravenous immunoglobulins (IVIgs), prepared from the collective plasma of several thousand donors are 
used in treatment of a broad spectrum of diseases. IVIg infusion, administered at replacement dosage, is the 
standard therapy for primary antibody deficiencies (PAD) such as CVID and XLA, aiming to replace the missing 
antibodies and thereby to prevent recurrent infections [54,74]. IVIg are also widely used as anti-
inflammatory therapy in a variety of acute and chronic autoimmune diseases; indeed, when administered at 
high dosages they exert an anti-inflammatory effect as demonstrated in different conditions like Kawasaki 
disease or Guillain-Barré syndrome. In vitro studies showed that IVIg has diverse effects on the immune 
system [189–191]. Poor information is available on the in vivo effects of IVIg administered at replacement 
dosages on human innate immune cells, including the monocyte/macrophage system [192]. Only recently, 
the mechanism by which IVIg mediated the effects on polymorphonuclear leukocytes (PMN) has been 
studied [193].  A recent study in patients with Common Variable Immune Deficiency (CVID) showed that IVIg 
infusion decreased the number of non-classical pro-inflammatory monocytes in vivo and suppressed the 
production of pro-inflammatory cytokines such as TNF-α in response to lipopolysaccharide (LPS) in vitro 
[194]. Moreover, IVIg untoward reaction has been also ascribed to neutrophils involvement in that IVIg might 
trigger PMN activation and degranulation [195–197]. On the other hand, other studies showed that IVIg 
might dampen the overall activity of PMN by inducing apoptosis [198–200], by decreasing the pro-
inflammatory activity [201] and by inhibiting PMN degranulation [202]. The different effect of IVIg on PMN 
activity depend by the dose administered. IVIg were able to activate PMN functions and prolong their survival 
in vitro, when tested at low concentration, while at higher concentration IVIg inhibit PMN activation in 
response to LPS and reduce the LPS-induced prolongation of lifespan [193]. However, caution should be used 
in that the different procedures used for PMN isolation might differently modulate cell responses, providing 
divergent results [203–205]. 
In light of these previous observations, mainly conducted in vitro, in this study we analyzed, in a cohort of 
CVID patients, the phenotype and functions of PMN and monocytes by the study of the expression of a panel 
of surface receptors, involved in cellular functionality, and by the study of oxidative burst and the phagocytic 
ability with the aim to understand if CVID patients display an altered innate immune compartment and if the 
IVIg infusion might affect monocytes and PMN functions. The effect of IVIg was evaluated by studying the 
PMN and monocytes before and after administration of IVIg in vivo. In detail, it was analyzed the expression 
of: 




- CD11b: a component of the phagocytic receptor αMβ2 or CD11b/ CD18. This receptor is expressed 
on human polymorphonuclear (PMN) leukocytes, NK cells and mononuclear phagocytes and it is 
involved in adhesion and phagocytosis process [206]. 
 
- CD11c: integrin molecule member of αXβ2 receptor that overlaps the properties of αMβ2 integrin in 
the adherence of neutrophils and monocytes to stimulated endothelium and in the phagocytosis of 
complement coated particles, overexpressed in inflammatory diseases such as rheumatoid arthritis 
(RA) [207, 208]. 
 
- Siglec 9: member of transmembrane sialic acid-binding proteins CD33-related, involved in adhesion 
process, broadly expressed on human blood phagocytes before IVIg [209,210], with a postulated 
inhibitory activity on the immune response through host and bacterial sialoglycans recognition 
[16,17] 
 
- CD181: a high affinity receptor for interleukin 8. Its activation induces (primarily in neutrophils) 
chemotaxis and also phagocytosis through the increase of intracellular Ca2+, exocytosis and the 
respiratory burst. [211] 
 
- CD66b: granulocyte activation marker involved in neutrophils cell adhesion, cell migration and 
pathogen binding [212,213]. In addition, monoclonal antibodies against the CD66 family members 
trigger an activation signal that regulate the adhesive activity of CD11b/CD18 [214]. CD66b is able to 
stimulate neutrophils and its crosslinking is able to induce the secretion of preformed interleukin-8 
(IL-8) [215].  
 
- CD16:  low affinity Fc receptor (also called FcγRIIIA). Since IgG FcγRs contribute to the anti-
inflammatory action of IVIg [216] and that CD16 receptor is involved in the mechanism of CD11b 
expression [217], both CD16 and CD11b may play in vivo critical roles in inflammatory responses [218] 
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In order to understand if the ability of innate immune cells, from CVID patients, to respond to bacterial 
stimulation is fully preserved, we also studied the expression of all these receptors after providing opsonized 
E. coli as stimulus before and after the IVIg infusion. In monocytes, the expression of these receptors was 
analyzed on all the three subsets. Moreover, considering the relationship between the expression of 
adhesion molecules and oxidative burst [219], we studied on PMN and monocytes the oxidative burst (also 
known as respiratory burst), a crucial reaction which consist in the rapid release of reactive oxygen species 
(ROS), necessary to degrade internalized particles. Given the dependence of the oxidative burst by 
phagocytosis, we also analyzed the phagocytic ability of monocyte and PMN with the purpose to understand 
whether phagocytosis is altered in CVID patients. The study of these processes provides insights on the 
overall killing ability of PMN and monocytes and hence on their ability to respond effectively to infections. 
In order to better understand the in vivo effect on PMN and monocytes of the immunoglobulins 
administration, we evaluated these processes also after IVIg infusion. In addition, we replicated the study on 
XLA which patients who receive an IVIg treatment similar to that of CVID patients. These experiments might 
be useful to understand whether the results obtained in CVID are also replicable in other PIDs. Moreover, 
considering that calcium mobilization is involved in ROS production and that FcγR clustering induce Ca2+ 
mobilization through the axis BTK-PLCγ2, it is possible that the lack of BTK in XLA patients could affect the 
calcium flux from internal storage and so compromise the ROS production [112]. Because numerous 
receptors utilize BTK as intracellular mediator, XLA patients can present defective responses of immune cells 
to activating stimuli; indeed, it was shown that BTK inhibitor could block degranulation and FcγR-mediated 
cytokine production in monocytes/macrophages [112]. Considering that calcium mobilization is the main 
event downstream the BTK activation as a result of FcγR clustering, we investigated if in XLA patients the 
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3. MATERIALS AND METHODS 
3.1 CVID PATIENTS 
Twenty-three CVID patients (12 males and 11 females; age range of 15–74 years; mean age: 50 ± 16.8 years) 
diagnosed according to the criteria of the European Society for Immune Deficiencies (http://www.esid.org) 
were enrolled in the study. All CVID patients were on replacement treatment with a cumulative monthly 
dosage of 300–400 mg/kg of IVIg administered every two-three weeks (Supplementary Table 1). Seventeen 
healthy donors (HD) (8 males and 9 females; age range 24–65 years; mean age 42.6 ± 13.6 years) were 
included as controls. The infusion time ranged from 1.5 h to 3 h. The infusion speed was established 
according to the individual tolerability. The mean IVIg dose administered on the day of blood sampling was 
28.9 ± 3.6 g. None of the patients was on steroids or immunosuppressive drugs at the time of the study. All 
subjects provided informed consent for blood sampling and processing, in accordance with the Institutional 
Review Board of the Sapienza University of Rome and with the Declaration of Helsinki. 
 
3.2 XLA PATIENTS 
Six male patients with XLA (age range of 20–60 years; mean age: 36.7 ± 15.4 years) and ten healthy donors 
(HD) male (age range of 27–58 years; mean age: 39.6 ± 9.8 years) were enrolled for the study. Patients were 
in a clinically stable situation without fever and not hospitalized. XLA was diagnosed according to the criteria 
of the World Health Organization scientific group for PIDs: mutation in BTK, absent BTK mRNA, absent BTK 
protein in monocytes or platelets, low levels of circulating B cells (measured by levels of CD19+ positive cells 
in blood samples), decreased or absent immunoglobulins in serum and a typical clinical history with recurrent 
bacterial infection or a positive family history.  XLA patients were on replacement treatment, with monthly 
dosage of 400-600 mg/kg of IVIg administered every three-four weeks (Supplementary Table 2). The infusion 
time ranged from 1.5 hours to 3 hours. The infusion speed was established according to the individual 
tolerability. All subjects provided informed consent for blood sampling and processing, in accordance with 
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3.3 BLOOD SAMPLES PREPARATION 
Heparinized whole blood samples were collected immediately before IVIg administration and within one 
hour after the infusion. These time points were chosen based considering that the highest increase of several 
cytokines plasma concentration occurs within one hour after IVIg infusion [220]. Total peripheral blood 
neutrophils and monocytes count was determined from blood cell counts and white blood cell differentials. 
For evaluating circulating cell without the harm of cell loss related to the density gradient centrifugation 
procedure, peripheral blood was lysed using lysing buffer (Becton Dickinson, BD) for 15 min at room 
temperature. Samples were washed twice for the following staining.  
 
3.4 ISOLATION OF PMN 
In a subgroup of CVID patients (n = 12) and HD (n = 8) isolation of PMN was performed using a double 
gradient formed by layering an equal volume of Histopaque-1077 over Histopaque-1119 (Sigma-Aldrich). 
Anticoagulated whole blood was layered onto the upper Histopaque-1077 and centrifuged at room 
temperature. The supernatant, plasma and remaining fluid were discarded and the PMN suspension (lower 
layer), transferred to a new tube and washed with isotonic phosphate buffered saline (PBS). The cells were 
centrifuged, washed by addition of PBS solution and suspended in PBS solution. 
 
3.5 PHENOTYPIC ANALYSIS OF MONOCYTE SUBPOPULATIONS 
Total peripheral blood monocyte count was determined from blood cell counts and white blood cell 
differentials. Peripheral blood were lysed with a fixed volume of Becton Dickinson lysing buffer lysed for 15 
min at room temperature, washed twice and stained (at 4°C for 30 min) with combinations of fluorochrome-
labeled antibodies. Monocytes subpopulations were phenotypically identified using anti-CD45, HLA-DR, 
CD14, and CD16 mAbs (BD, Becton- Dickinson Biosciences, Franklin Lakes, NJ), gating on CD14+ HLA-DR+ 
monocytes and then classified according to their expression of CD14 and CD16 into classical (CD14++CD16-), 
intermediate (CD14++CD16+) and non classical monocytes (CD14+CD16++) using a 4-color flow cytometry 
single platform assay. An isotype control (IgG1, BD) was run in parallel in order to set a threshold for 
distinguish intermediate monocytes (CD16+) from classical monocytes (CD16-). Monocyte subpopulations 
were then analyzed in parallel for the expression of surface receptors CD181, CD11b, CD11c and Siglec 9 
using various combinations of fluorochrome-labeled antibodies. The corresponding isotype controls (IgG1, 
BD) for each receptor was run in parallel. 30.000 events were counted per sample. Flow cytometric analysis 
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was done with a FACSCalibur instrument (BD) using CellQuest (BD) and FlowJo (TreeStar, Ashland, Ore) 
software. Results were expressed as geometric mean Fluorescence Intensity (MFI) of any given marker within 
the defined population. All antibodies were obtained from BD Biosciences. 
 
3.6  ANALYSIS OF RECEPTORS EXPRESSION ON PMN  
The expression of CD181, CD66b, CD11b, CD11c, CD16 and Siglec 9 was evaluated on PMN from whole blood 
samples lysed for 15 min at room temperature and performing a staining at 4°C for 30 min with combinations 
of fluorochrome-labeled antibodies. Samples were washed, suspended in ice cold PBS and analyzed by flow 
cytometry. Whereas the conditions in which the PMN are analyzed seem to influence their responses [203-
205] we verify the differences between whole blood condition and isolation PMN in terms of receptors 
expression, therefore in a subgroup of patients we performed the analysis of CD11b, Siglec 9 and CD16 
expression both in whole blood condition and on isolated PMN (1-2 x 105cells).  In CVID patients PMN were 
identified by forward scatter (FSC) and side scatter (SSC) characteristics and gating on CD14 negative events 
in order to exclude monocytes (Supplementary Fig. 1A–D). In parallel, we performed the same procedure 
using CD15 antibody to further identify neutrophils (Supplementary Fig. 1E–H). In XLA patients PMN were 
identified by forward scatter (FSC) and side scatter (SSC) characteristics and gating on CD15 positive events 
(Supplementary Fig. 3). 30.000 events were counted per sample. Flow cytometric analysis was done with a 
FACSCalibur instrument (BD) using CellQuest (BD) and FlowJo (TreeStar, Ashland, Ore) software. Results were 
expressed as geometric mean Fluorescence Intensity (MFI) of any given marker within the defined 
population. All antibodies were obtained from BD Biosciences 
 
3.7 MONOCYTES AND PMN STIMULATION BY ESCHERICHIA COLI 
100 µL of whole blood, collected before and after IgG administration, were added to 20 µl of pre-cooled 
opsonized not labeled whole Escherichia coli (E. coli) at a concentration of 1-2x109/ml (Glycotope, 
Biotechnology). Samples were incubated in water bath for 20 min at 37°C and lysed for 15 min at room 
temperature. Cells stimulated were stained at 4°C for 30 min with fluorochrome-conjugated antibodies in 
various combinations to evaluate the expression of the receptors described above. 30.000 events were 
counted per sample. Flow cytometry analysis were done with a FACSCalibur instrument using CellQuest and 
FlowJo software.  
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3.8 MONOCYTES AND PMN OXIDATIVE BURST ACTIVITY 
The evaluation of leukocyte oxidative burst was determined with PHAGOBURST assay (Glycotope, 
Biotechnology), according to the manufacturers’ instructions. Whole blood samples (100 μl) were incubated 
in a water bath for 20 min at 37°C with opsonized E. coli (1-2x109/ml)). For PMN we provided also PMA (1.62 
mM) as strong stimulus. The intracellular production of superoxide anions and hydrogen peroxide in 
monocytes and neutrophils in response to phagocytosis of bacteria was tested by using of the fluorescence 
probes DHR 123. The amount of ROS produced was reported as MFI.  In addition, we performed in XLA 
patients the study of oxidative burst also using BAPTA-AM (Unimed Scientifica) as calcium chelator, in order 
to verify the Ca2+-dependence production of ROS triggered by FcγR stimulation.  Whole blood samples were 
pre-treated with 100 μM of the calcium chelator BAPTA-AM for 30 min and then they were incubated in a 
water bath for 20 min at 37°C with opsonized E. coli (1-2x109/ml) according to the manufacturers’ 
instructions of PHAGOBURST assay.  
FSC and SSC characteristics were used to identify the PMN population and to gate out other cells or debris. 
30.000 events were counted per sample. The oxidation lead to fluorescence detected by flow cytometry, 
using the blue-green excitation light (488 nm argon-ion laser).  
 
3.9 MONOCYTES AND PMN PHAGOCYTOSIS  
The quantitative determination of leukocyte phagocytosis was determined with PHAGOTEST assay 
(Glycotope, Biotechnology), according to the manufacturers’ instructions. Whole blood samples (100 μl) 
were incubated in a water bath for 10 min at 37°C with FITC-labeled E. coli (2x109/ml). The percentage of 
cells having performed phagocytosis (granulocytes and monocytes) was analyzed as well as their MFI 
(number of ingested bacteria). In addition, we tested in XLA patients, the effect of calcium chelator on 
phagocytosis in order to verify the Ca2+-independence of the process. Whole blood samples were pre-treated 
with 100 μM of the calcium chelator BAPTA-AM for 30 min and then they were incubated in a water bath for 
10 min at 37°C with FITC-labeled E. coli (2x109/ml) according to the manufacturers’ instructions of 
PHAGOTEST assay.  FSC and SSC characteristics were used to identify the monocytes and PMN populations 
and to gate out other cells or debris. 30.000 events were counted per sample. Cells were analyzed by flow 
cytometry using the blue-green excitation light (488 nm argon-ion laser).  
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3.10 STATISTICAL ANALYSIS 
Data were analyzed using the Mann-Whitney U test for unpaired two groups or by paired Wilcoxon test. 
Correlations were calculated by means of linear regression analysis.  Data were analyzed with StatView 5.0.1 




























4.1 IDENTIFICATION OF MONOCYTE SUBSETS 
The expression of CD14 and CD16 receptors allowed identifying three monocyte subsets [11]: classical 
monocytes showing high CD14 expression and the absence of CD16 expression (CD14++CD16−), intermediate 
monocytes showing a high level of CD14 with low CD16 expression (CD14++CD16+), and non-classical 
monocytes expressing a low level of CD14 with high CD16 expression (CD14+CD16++). Initially, a threshold 
was set on CD45 staining in order to exclude non-leucocyte events. In the CD45+ side/scatter plot, a gate was 
set around monocyte population (Fig. 3A). Events in this gate were shown in a CD14/HLA-DR plot and here 
a gate was defined including CD14+ and HLA-DR+ events (Fig. 3B). To determine the boundary between 
intermediate and classical monocyte subsets an isotype IgG control was used (Fig. 3C). Events in this gate 
were shown in a CD14/CD16 plot and here three different subsets of monocyte were identified (Fig. 3D-F). 
 
4.2 MONOCYTE SUBSETS IN CVID PATIENTS AND HD. EFFECT OF IVIG INFUSION.  
Absolute counts of total monocytes, of classical and non-classical monocytes did not show any significant 
difference between CVID, and HD. Data from a representative HD and from a CVID patient before and after 
IVIg infusion were shown in Fig. 3D–F. Classical monocytes were the prevalent monocyte subset in patients 
and HD (78,6 % ± 10,2 vs 77,9 ± 8,2 respectively)  while intermediate monocyte frequencies were higher in 
CVID patients than in HD (11,4 ± 6,7 vs  6,1 % ± 1,1  respectively, p= 0.008) and non classical were lower in 
CVID patients than in HD (10,0 ± 5,3 vs 16,1 % ± 8,5 respectively p= 0.04) (Fig. 4). Within 1 h after IVIg infusion, 
while the absolute leukocytes count did not change, we observed an average reduction of 23% of the total 
monocyte population (table 4). However, this decrease was not uniform within monocytes subsets since the 
frequency of non-classical monocyte did not change (from 10,0 ± 5,3 to 7,7 ± 5,5 p= ns )  (Fig. 4A), the 
percentage of intermediate monocytes decreased (from 11,4 ± 6,7 to 7,7 ± 5,4 p= 0.002)  (Fig. 4B) reaching 
a value similar to that found in HD and the percentage of classical monocytes increased (from 78,6 ± 10,2 to 











Figure 3 Identification of monocyte subpopulations. Plot A: CD45+monocytes and adjacent lymphocytes, including NK 
cells. Cells were gated to exclude CD14-/HLA-DR (plot B, cells outside the gate). To determine the boundary between 
intermediate and classical monocyte subsets an isotype control was used (plot C). Monocyte subsets were analyzed 
for CD14 and CD16 expression in a representative healthy donor (plot D) and in a CVID patient before (plot E) and 
after IVIg infusion (plot F). Percentages denote mean values. 
Table 4. Peripheral blood monocytes, and monocyte subsets in healthy donors, patients with CVID before IVIg and 1 h 
after IVIg administration in vivo. Results are expressed as absolute counts. p values are shown for absolute numbers: 



















Figure 4. Frequencies of non-classical (A), 
intermediate (B) and classical (C) monocytes. 
Data show monocyte frequencies (expressed 
as % of total monocytes) from blood samples 
collected immediately before and within 1 h 
after IVIg infusion of HD and CVID patients. 
Results are expressed as percentages. Bars 




4.3 RECEPTORS EXPRESSION ON MONOCYTES IN CVID PATIENTS AND HD. EFFECT OF IVIG INFUSION 
In CVID and HD, the expression of CD11b was higher in classical than in intermediate monocytes, while it was 
almost undetectable in non-classical monocytes (Fig. 5 A). A significant difference in CD11b expression 
between HD and CVID was evident in the classical monocyte subset (58 ± 12.7 MFI vs 93.8 ± 25.9 MFI 
respectively p= 0.006), while no difference was observed in intermediate monocytes (38.3 ± 20.3 MFI vs 45.5 
± 22.6 MFI respectively) and non-classical monocytes (2.9 ± 1.4 MFI vs 2 ± 0.7 MFI respectively). After IVIg, 
CD11b expression on classical monocytes decreased (from 93.8 ± 25.9 MFI to 69.2 ± 30.7 MFI p= 0.006) and 
returned to values similar to those observed in HD. The CD11b expression on intermediate and non-classical 
monocytes did not change after IVIg (from 45.5±22.6MFI to 46.3±26.8 MFI, from 2±0.8 MFI to 2.4±0.9MFI 
respectively) (Fig.5A). 
The postulated inhibitory activity of Siglec 9 on the immune response through host and bacterial sialoglycans 
recognition [221,222] prompted us to verify its expression on monocyte subsets at baseline and after IVIg. 
In HD and in CVID, Siglec 9 expression was evident on all monocyte subsets, and it was higher on classical 
and on intermediate than on non-classical monocytes. A significant difference in Siglec 9 expression between 
HD and CVID was evident on the classical monocyte subset (93.4 ± 26.5 MFI vs 157.3 ± 89.8 MFI respectively 
p= 0.04). No difference was observed on intermediate monocytes (112.2±22.3MFI vs 146.6±82.4MFI 
respectively) and on non-classical monocytes (58.3 ± 10 MFI vs 64.1 ± 22.4 MFI respectively) (Fig. 5B). After 
IVIg, Siglec 9 expression on classical monocytes slightly decreased (from 157.3 ± 89.8 MFI to 132.2 ± 61.1 
MFI, p= 0.003) but did not change on intermediate (from 146.6±82.4MFI to 141.8±62.2 MFI) and on non-







The role of CD11c in adherence and phagocytosis process and its overexpression in inflammatory disease 
such as RA [207,208] led us to investigate its expression in CVID patients. Both in CVID and HD the expression 
of CD11c showed no significant differences among the three monocytes subsets (Fig. 6). Despite to what 
observed for CD11b, we did not find any difference in CD11c expression level between HD and CVID as shown 
in Figure 6 (non classical 48,8± 14,8 MFI vs  57,1± 35.2 MFI; intermediate 59,9 ± 24.3 MFI vs 65,4 ± 17 MFI; 
classical 40,2 ± 19.3 MFI vs 43.3 ± 7.9 MFI respectively). After IVIg, CD11c expression did not change in any 
monocytes subsets (non classical: from 57,1± 35.2 MFI to 59.2 ± 39.2 MFI; intermediate:  from 65,4 ± 17 MFI 
to 64.0 ± 25.7 MFI; classical: from 43.3 ± 7.9 MFI to 40.2± 10.8 MFI). 
Figure 5. Effect of IVIg on CD11b (A) and Siglec 9 (B) expression in classical, intermediate and non classical 











Since the role played by CD181 in monocytes activity, we evaluated its surface expression with the aim to 
obtain insights regards the activation status of monocytes and their responsiveness to IL-8. As shown in 
Figure 7 we found that, in all monocytes subpopulations, CD181 was expressed at similar level in HD and 
CVID (non classical 7 ± 1 MFI vs 7.5± 1.7 MFI; intermediate 9,8 ± 2.8 MFI vs 11 ± 3.5 MFI; classical 9,6 ± 1.7 
MFI vs 9.9 ± 2.6 MFI respectively) and that IVIg administration did not induce any variation of its expression 
(non classical: from 7.5± 1.7 MFI to 7.4 ± 1.5 MFI; intermediate:  11 ± 3.5 MFI to 10.3 ± 4.1 MFI; classical: 
from 9.9 ± 2.6 MFI to 9.7± 2.8 MFI). 
 
Figure 6. CVID patients show a similar CD11c expression on monocytes subsets compared to HD. After IVIg infusion the 
expression of CD11c on monocytes subsets remained unaltered. Results are expressed as Mean Fluorescence 










4.4 ESCHERICHIA COLI STIMULATION OF MONOCYTES SUBSETS 
In order to assess if IVIg might affect the monocytes' ability to respond to opsonized E. coli in terms of 
receptors expression, we evaluated the expression of CD11b, CD11c, Siglec 9 and CD181 on the overall 
monocytes population. We found that monocytes from CVID patients were able to overexpress all the 
receptors analyzed after stimulation with E. coli and that these overexpression were similar to those 
observed in healthy donors. Moreover, we found that the overexpression of all receptors was preserved also 
after IVIg infusion.  In detail: CD11b, HD from 57.1 ± 13.2 MFI to 129.5 ± 38.9 MFI, CVID before IVIg: from 
80.4 ± 23.9 MFI to 125.7 ± 28.5 MFI, CVID after IVIg: from 67.2 ± 31.8 MFI to 126 ± 36.9 MFI, (Fig. 8); Siglec 
9, HD: from 123.5 ± 86.6 MFI to 168.7 ± 62.9 MFI, CVID before IVIg: from 129.6 ± 23.1 MFI to 174.1 ± 31.4 
MFI,  CVID after IVIg from 116.2 ± 24 MFI to 172.6 ± 23.4 MFI, (Fig. 9); CD181, HD: from 9.7 ± 1.2 MFI to 26.4 
± 8.7 MFI, CVID before IVIg: from 9.0 ± 1.6 MFI to 24.5 ± 5.0 MFI,  CVID after IVIg from 9.6 ± 2.9 MFI to 26.0 
± 3.7 MFI, (Fig. 10); CD11c, HD: from 37.0 ± 18.5 MFI to 97.6 ± 37.1 MFI, CVID before IVIg: from 41.3 ± 12.6 
MFI to 104.0 ± 23.2 MFI,  CVID after IVIg from 41.6 ± 10.7 MFI to 109.3 ± 23.1 MFI, (Fig. 11). All p values are 
shown in figures.  
Figure 7. CVID patients show a similar CD181 expression on monocytes subsets compared to HD. After IVIg infusion the 
expression of CD181 on monocytes subsets remained unaltered. Results are expressed as Mean Fluorescence 




 Finally, we also studied how the overexpression of these receptor, induced by opsonized E. coli, was 
distributed among the three monocytes subsets finding that it occurred in all subsets except the expression 
of Siglec 9 on non classical monocytes that do not seem to be induced by the stimulus, suggesting that non 
classical monocytes could not be mainly involved in phagocytosis (considering the damping effect of Siglec 9 
when it recognize sialic acid residues), although for all other receptors we observed the overexpression even 
in non classical subset (Tab. 5). The receptors’ overexpression seem was preserved also after IVIg infusion 















Figure 8. Effect of E. coli stimulation on CD11b expression in HD and CVID 
patients before and after IVIg infusion. CD11b expression increased after E. 
coli stimulation before IVIg infusion as well as 1 h after IVIg. Bars denote 
the standard deviations. 
Figure 9.  Effect of E. coli stimulation on Siglec 9 expression in HD and CVID 
patients before and after IVIg infusion. Siglec 9 expression increased after 
E. coli stimulation before IVIg infusion. Siglec 9 overexpression was 






















      
Figure 10.  Effect of E. coli stimulation on CD181 expression in HD and CVID patients 
before and after IVIg infusion. CD181 expression increased after E. coli stimulation 
before IVIg infusion. CD181 overexpression was preserved after the infusion. Bars 
denote standard deviations. 
Figure 11.  Effect of E. coli stimulation on CD11c expression in HD and CVID patients 
before and after IVIg infusion. CD11c expression increased after E. coli stimulation 
before IVIg infusion. CD11c  overexpression was preserved after the infusion. Bars 




4.5  RECEPTORS EXPRESSION ON PMN IN CVID PATIENTS AND HD AND E. COLI STIMULATION. EFFECT OF IVIG INFUSION 
The activation status of PMNs is strongly influenced by their ability to perform phagocytosis, respiratory 
burst and adhesion processes, therefore we evaluated the expression level of CD181, CD66b, CD11b, CD11c, 
CD16 and Siglec 9 receptors. As shown in Fig 12 PMN from CVID and HD showed an overlapping expression 
of all receptors suggesting that unlike monocytes, PMNs of CVID patients exhibit a normal phenotype. After 
IVIg infusion the expression of all receptors remained unaltered except the expression of CD181 that 
decrease after IVIg infusion (p=0.0005) (Fig 12, Table 6). Moreover, we found that PMN stimulation by 
opsonized E. coli induced an overexpression of CD66b, CD11b, CD11c, CD16 and Siglec 9 receptors both in 
CVID and in HD and that also after IVIg infusion the overexpression was preserved (Table 6) suggesting that 
the pathway by which these receptors were overexpressed, through the clustering of FcγRs, was intact in 
CVID and that IVIg do not alter in any way the process. On the contrary and in line with previous studies [223] 
we found a decreased expression of CD181 after stimulation with E. coli both in HD and CVID and the 
reduction of CD181 expression was confirmed also after IVIg infusion (table 6).  
Finally, we found that the overexpression of CD11b induced by E.coli, although occur both in patients and in 
HD, it is higher in CVID (5.2 ± 6.5 vs 20.2 ± 21.1 respectively). The reason for the greater overexpression of 
CD11b in CVID is attributable to only 8 patients who responded excessively to the stimulation, however, we 




Table 5 Receptors expression on monocytes’ subsets from HD and CVID patients. Values are expressed as Mean 
Fluorescence Intensity (MFI). UN: Unstimulated; ST: Stimulated with E. coli. ‡ p= 0.002  • p= 0.003 * p= 0.01 ▪ p= 









Table 6. Receptors expression on 
PMNs from HD and CVID patients. 
Values are expressed as Mean 
Fluorescence Intensity (MFI) 
Statistical significance, determined 
by the nonparametric Wilcoxon 
Signed Rank, is indicated as p value 
* p=0.012 ‡ p= 0.0007 ◦ p=0.04 
▪p=0,003 ***p=0.001 ●p=0.0002 
◊p=0.0001 
Figure 12. CD181, CD11b, CD11c 
and Siglec 9 expression on PMN 
from HD and CVID patients before 
and after IVIg infusion. Whole blood 
samples were analyzed for the 
expression of CD181, CD66b, 
CD11b, CD11c, CD16 and Siglec 9 
before and after IVIg infusion. The 
expression of all surface receptors 
was evaluated by performing a 
staining at 4°C for 30 min with 
specific fluorochrome-labeled 
antibody. Samples were washed, 
suspended in ice-cold PBS and 
analyzed by flow cytometry. CVID 
patients and HD show a similar 
receptors expression. Soon after 
IVIg infusion only the expression of 
CD181 decrease (Plot A). Results 
are expressed as Mean 
Fluorescence Intensity. Histograms 
denote mean values and bars 
standard deviation. Statistical 
significance, determined by the 
nonparametric Wilcoxon Signed 





4.6 ISOLATED PMN SURFACE RECEPTORS ANALYSIS AND IN VIVO EFFECT OF IVIG INFUSION  
In a subgroup of CVID patients we analyzed the expression of CD16, CD11b and Siglec 9 both in isolated PMN 
and whole blood condition, in order to clarify if isolation might affect the surface receptors expression. PMN 
isolated from CVID and HD showed a similar expression of CD16 (CVID: 1715 ± 261.6 MFI vs HD: 1929 ± 100.4 
MFI); CD11b (CVID: 18.7 ± 11.8 MF vs HD: 20.5 ± 7.2 MFI) Siglec 9 (CVID: 49.6 ± 2.3 MFI vs HD: 54.8 ± 4.5 
MFI). IVIg administration did not alter the receptors expression (CD16: 1631.5 ± 355.6 MFI; CD11b: 19.8 ± 
7.7 MFI; Siglec 9: 47.8 ± 2.7 MFI) (Fig. 13A–C). Our results show that, while the CD16 and Siglec 9 expression 
was similar in both experimental conditions, the expression of CD11b is increased on isolated PMN (p = 0.01) 
(Fig. 13B) demonstrating that the isolation procedure might alter surface receptors expression.  
4.7 MONOCYTES OXIDATIVE BURST  
The intracellular production of superoxide anions and hydrogen peroxide by monocytes in response to 
phagocytosis of bacteria was tested by the use of the fluorescence probes DHR 123. The oxidation leads to 
fluorescence detected by flow cytometry, using the blue-green excitation light (488 nm argon-ion laser). We 
analyzed the MFI of cells producing reactive oxygen species after E. coli stimulation (Fig. 14A). E. coli 
stimulation induced a comparable monocyte oxidative burst in HD and in CVID patients (150.8 ± 52.4 MFI vs 
166.7±97.9 MFI, respectively) (Fig. 14B), even if the data obtained in CVID were more dispersed than those 
obtained in HD. In particular, a very high level of oxidative burst was evident in three CVID patients, anyway 
the amount of ROS production did not correlate with any clinical complications. After IVIg infusion, monocyte 
Figure 13.Comparison between the expression of CD16 (A), CD11b (B) and Siglec 9 (C) on isolated PMN and whole blood 
in CVID and HD patients.. The expression of these receptors on isolated PMN from HD is similar to that observed on 
PMN from CVID patients and remain unaltered after IVIg infusion. CD16 and Siglec 9 expression was similar on PMN 




oxidative burst slightly decreased in all CVID patients (from 166.7 ± 97.9 MFI to 141.1 ± 92.1 MFI, p=0.004), 
as shown in Fig. 14B, suggesting a slight damping effect of IVIg infusion.  
 
4.8 PMN OXIDATIVE BURST  
The PMN oxidative burst was evaluated by using opsonized E. coli and PMA in whole blood conditions. E. coli 
induced a similar oxidative burst in CVID and HD (CVID: 519.8 ± 203.1 MFI; HD: 508.8 ± 137.7 MFI), once 
again a greater data dispersion was observed in CVID (Fig. 15A–B). One hour after IVIg, the E. coli-induced 
oxidative burst was comparable to that observed prior the infusion (before IVIg: 519.8 ± 203.1 MFI; after 
IVIg:  539.5 ± 301.4 MFI) (Fig. 15C–D). On the contrary, PMA induced a more intensive oxidative burst was in 
CVID than in HD (940.2 ± 317.1 MFI and 470.4 ± 280.3 MFI, respectively, p= 0.004) (Fig. 16A–B). In CVID 
patients the PMA-triggered oxidative burst decreased from 940.2 ± 317.1 MFI to 771.2 ± 348.8 MFI (p= 0.02) 
after IVIg infusion (Fig. 16C–D).  E. coli–induced oxidative burst on PMN and on monocytes of individual CVID 
patients were strongly related in samples collected before IVIg (R = 0.81, p < 0.0001) and after IVIg (R = 0.8, 
p < 0.001). Unfortunately, we could not found any clinical associations with PMN oxidative burst and PMN 





Figure 14. Monocytes oxidative 
burst after E. coli stimulation in a 
representative CVID patient before 
and after IVIg infusion. Panel A: dot 
plots showing the electronic gate 
of monocytes population. 
Histograms denote fluorescence 
intensities in unstimulated 
monocytes (solid histograms) and 
in E. coli stimulated monocytes 
before IVIg infusion (thin lines) and 
after IVIg infusion (thick lines). The 
x-axis denotes the fluorescence of 
rhodamine 123 (R 123) produced 
by the oxidation of 
dihydrorhodamine 123 (DHR 123). 
Panel B: monocytes oxidative burst 
after E. coli stimulation in HD, in 
CVID pre-IVIg and 1 h post-IVIg 















Figure 15. PMN oxidative burst induced by E. coli in HD and CVID patients. The 
quantitative leukocyte oxidative burst evaluated by incubating whole blood 
samples in a water bath at 37 _C for 20 min with opsonized E. coli (1–2 _ 109/ml). 
The conversion of DHR 123 to R 123 were used to evaluated the intracellular 
ROS production. CVID patients showed a normal PMN oxidative burst when 
stimulated by opsonized E. coli (A, B). IVIg administration didn’t affect PMN ROS 
production (C, D). PMN population was identified by flow cytometry using FSC 
and SSC characteristics. Results are expressed as Mean Fluorescence Intensity. 
A horizontal bar denotes the mean values. Statistical significance indicated as p 
value were determined by the nonparametric Mann-Whitney test (B) and 





4.9  MONOCYTES AND PMN PHAGOCYTOSIS  
Since phagocytosis is a fundamental step for the resolution of infections, we evaluated in CVID patients the 
process using FITC-labeled opsonized E. coli with the aim to test the ability of monocytes to internalize 
bacteria through FcγR. Our results show that monocytes from CVID patients perform a similar phagocytosis 
compared to HD (CVID: 428.1 ± 137.0 MFI vs HD: 386.8 ± 154.4 MFI) (Fig. 17A) but one hour after IVIg, 
phagocytosis ability decreased (from 428.1 ± 137.0 MFI to 373.1 ± 120.4 MFI, p=0.02) (Fig. 17A), similarly as 
observed for the oxidative burst. We observed also a normal phagocytosis performed by PMN from CVID 
(CVID: 612.0 ± 214.5 MFI vs HD: 663.8 ± 160.8 MFI) (Fig. 17B). After IVIg infusion, phagocytosis remains 
unaltered (612.0 ± 214.5 MFI to 582.5 ± 179.1 MFI) (Fig. 17B) demonstrating that IVIg treatment did not 
affect the ability of PMNs of CVID patients to perform a bacterial phagocytosis as the subsequent oxidative 
burst. 
Figure 16 PMN oxidative burst 
induced by PMA in HD and CVID 
patients. The quantitative leukocyte 
oxidative burst was evaluated by 
incubating whole blood samples in a 
water bath at 37°C for 20 min with 
PMA (1.62 mM). The conversion of 
DHR 123 to R 123 were used to 
evaluated the intracellular ROS 
production. CVID patients showed 
an increased oxidative burst when 
stimulated with PMA in comparison 
to HD (A, B). IVIg infusion reduced 
ROS production (C, D). PMN 
population was identified by flow 
cytometry using FSC and SSC 
characteristics. Results are 
expressed as Mean Fluorescence 
Intensity. A horizontal bar denotes 
the mean values. Statistical 
significance indicated as p value 
were determined by the 
nonparametric Mann-Whitney test 







4.10 MONOCYTE SUBSETS IN XLA AND THE EFFECT OF IVIG INFUSION 
Monocytes subsets were identified according to their expression CD14 and the CD16 in classical, 
intermediate and in non classical (Supplementary Fig. 2). We observed that the classical monocytes were the 
most frequent subpopulation in XLA patients and HD (XLA: 76.8 ± 3.8% and HD: 84.4 ± 3.3%). Furthermore, 
we observed a similar percentage of non-classical monocytes in XLA and HD (XLA before IVIg: 5.9 ± 2.7% and 
HD: 7.0 ± 3.0%), while the intermediate subset was increased in patients compared to HD (XLA before IVIg: 
17.2 ± 2.9% and HD: 8.4 ± 3.2%, p= 0.01) (Fig. 18). After the IVIg infusion, we observed a decrease of 
intermediate monocytes percentage (from 17.1 ± 2.9% to 14.2 ± 3.2%, p 0.04) even if they remain more 
represented respect to HD (14.2 ± 3.2% vs 8.4 ± 3.2%, respectively p =0.01). The frequency of non-classical 
and classical monocytes did not change after the infusion (from 5.9 ± 2.7% to 5.5 ± 2.4%; from 76.8 ± 3.8% 
to 80.2 ± 3.2% respectively) (Fig. 18).     
 
 
Figure 17.  Monocytes and PMN phagocytosis in CVID patients and HD. The quantitative determination of leukocyte 
phagocytosis was tested by incubating whole blood samples in a water bath for 10 min at 37°C with FITC-labeled 
E. coli (2x109/ml). The percentage of cells having performed phagocytosis (granulocytes and monocytes) was 
analyzed as number of ingested bacteria and results are expressed as Mean Fluorescence Intensity. CVID patients 
show an increased monocytes phagocytosis (plot A) than HD while PMN (plot B) performed a similar phagocytosis 
compared to HD. After IVIg administration monocytes phagocytosis decreased, while it remains unchanged in 
PMN. Results are expressed as Mean Fluorescence Intensity. Histograms denote mean values and bars standard 
deviation. Statistical significance, determined by the nonparametric Mann Whitney and Wilcoxon Signed Rank test 
















4.11 MONOCYTES SURFACE RECEPTORS IN XLA 
With the aim to obtain insights regards the activation status of monocytes we evaluated the surface 
expression of CD181, CD11b, CD11c and Siglec 9 as receptors involved in cellular responses. As shown in 
Table 6 we found that, in the three monocytes subpopulations, all these receptors were expressed at a 
similar level in XLA patients and in HD and that IVIg administration did not induce any variation of their 




Figure 18.  Frequencies of non classical, intermediate and classical monocytes from HD and XLA patients before and after 
IVIg infusion. Whole blood samples were analyzed for the expression of CD16 and CD14 before and after IVIg infusion. 
Histograms show that non classical and classical monocyte frequencies from XLA patients are similar to that observed 
on HD and that IVIg infusion did not change their frequency. Intermediate monocytes percentage is increased in XLA 
patients (▪p 0.01), IVIg infusion induce their reduction (▪▪p 0.04) even if remained at higher level respect to HD (▪▪▪p 
0.01). Results are expressed as percentages. Histograms denote mean values and bars standard deviation. Statistical 











Figure 19 CD181 (A), CD11b (B), CD11c (C) and Siglec 9 (D) expression on monocytes subsets from HD and XLA patients 
before and after IVIg infusion. Whole blood samples were analyzed for the expression of CD181, CD11b, CD11c and 
Siglec 9 before and after IVIg infusion. The expression of all surface receptors was evaluated by performing a staining 
at 4°C for 30 min with specific fluorochrome-labeled antibody. Samples were washed, suspended in ice-cold PBS and 
analyzed by flow cytometry. XLA patients show a similar CD181, CD11b, CD11c and Siglec 9 expression on monocytes 
subsets compared to HD. After IVIg infusion the expression of all receptors on monocytes subsets remained unaltered. 






4.12 STIMULATION OF MONOCYTES IN XLA PATIENTS  
With the aim to verify if IVIg influence the monocytes' ability to express CD181, CD11b, CD11c and Siglec 9 
following stimulation through FcγR, we provided opsonized E. coli as stimulus and we analyzed the 
expression of surface receptors on monocytes subsets. We found that opsonized E. coli induced, in whole 
blood conditions, a similar increase of all receptors in XLA patients and HD (Table 7). The overexpression of 
these receptors induced by E. coli was preserved also after IVIg infusion, demonstrating that in vivo IVIg 
replacement did not influence the monocytes ability to overexpress surface receptors in response to 
bacterial stimulus (Table 7). 
 
4.13 PMNS SURFACE RECEPTORS  
The activation status of PMNs is strongly influenced by their ability to perform phagocytosis, respiratory 
burst and adhesion processes; therefore, we evaluated the expression level of CD181, CD66b, CD11b, CD11c, 
CD16 and Siglec 9 receptors. As shown in Table 8, PMN from XLA and HD showed an overlapping expression 
of all receptors with the exception of CD66b that was overexpressed in XLA patients (XLA before IVIg 484.7 
± 66 MFI vs HD 333.5 ± 29 MFI, p=0.001). After IVIg infusion the expression of all receptors remained 
unaltered (Fig. 20A-F) demonstrating, like previously shown in CVID patients, that IVIg did not influence the 
PMNs’ phenotype. 
Table 7 Receptors expression on monocytes’ subsets from HD and XLA patients. Values are expressed as Mean 
Fluorescence Intensity (MFI) ± standard deviation. All the receptors showed a significant increase of their expression 














Figure 20 CD181 (A), CD66b (B) CD11b (C), CD11c(D), CD16 (E) and Siglec 9 (F) expression on PMN from HD and XLA 
patients before and after IVIg infusion. Whole blood samples were analyzed for the receptors’ expression. The 
expression of all surface receptors was evaluated by performing a staining at 4°C for 30 min with specific 
fluorochrome-labeled antibody. Samples were washed, suspended in ice-cold PBS and analyzed by flow cytometry. 
XLA patients and HD show a similar CD181, CD11b, CD11c, CD16 and Siglec 9 expression, while CD66b expression 
was overexpressed on PMN from XLA patients compared to HD (▪p 0.01). After IVIg infusion, the expression of all 
receptors remained unaltered. Results are expressed as Mean Fluorescence Intensity. Histograms denote mean 
values and bars standard deviation. Statistical significance, determined by the nonparametric Mann Whitney test, is 
indicated as ▪p value. 
Table 8. Receptors expression on PMNs from HD and XLA patients. Values are expressed as Mean Fluorescence Intensity 
(MFI), Statistical significance, determined by the nonparametric Wilcoxon Signed Rank test, is indicated as p value. 




4.14 STIMULATION OF PMNS IN XLA PATIENTS 
PMN stimulation by opsonized E. coli induced an overexpression of all the analyzed receptors on PMN from 
XLA patients and HD except CD181, which was reduced after stimulation, in line with that, previously 
observed in CVID patients (Table 7). As indicated in table 7, PMNs from XLA patients showed a greater 
increase of CD11b compared to HD as previously seen in CVID patients. The receptors’ overexpression 
induced by E. coli was preserved also after IVIg infusion showing that IVIg replacement did not affect the 
PMN ability to respond to opsonized bacteria. 
 
4.15 MONOCYTES OXIDATIVE BURST IN XLA PATIENTS 
The oxidative burst reflects the killing ability of innate immune cells and involve many cellular component 
and pathways. The lack of BTK activity might influence the respiratory burst considering that is a process that 
require Ca2+ mobilization from internal storage. Therefore, we evaluated the monocytes ROS production in 
XLA patients after stimulation ex vivo with opsonized E. coli and PMA (Fig. 21A-B). We found that both E. coli 
and PMA induced a comparable oxidative burst in monocytes from XLA patients and HD (E. coli: 176.5 ± 33.6 
MFI vs 185.2 ± 40 MFI, respectively; PMA: 375 ± 30.6 MFI vs 350.3 ± 50.2 MFI, respectively). After IVIg 
infusion, monocyte oxidative burst induced by E. coli slightly decreased (from 176.5 ± 33.6 MFI to 152.8 ± 
33.3 MFI, p 0.004) as previously observed on CVID monocytes, but remain unaltered when PMA was provided 


































Figure 21 Monocytes oxidative burst in XLA 
patients and HD. The quantitative evaluation of 
leukocyte oxidative burst was observed by 
incubating whole blood samples in a water bath at 
37°C with opsonized E. coli (1-2x109/ml) and PMA 
(1.62mM). The conversion of DHR 123 to R 123 
were used to evaluated the intracellular ROS 
production. XLA patients show a similar 
monocytes E. coli-induced (plot A) and PMA-
induced (plot B) oxidative burst compared to HD. 
After IVIg, monocyte oxidative burst slightly 
decreased (p 0.004), but remain unaltered when 
PMA was provided. Results are expressed as Mean 
Fluorescence Intensity. Histograms denote mean 
values and bars standard deviation. Statistical 
significance, determined by the nonparametric 





4.16 PMN OXIDATIVE BURST IN XLA PATIENTS  
The PMNs intracellular production of superoxide anions and hydrogen peroxide in response to phagocytosis 
was tested by using the fluorescence probes DHR 123. We analyzed the MFI of cells producing reactive 
oxygen metabolites after E. coli and PMA stimulation. Both stimuli induced a comparable PMN oxidative 
burst in XLA patients and HD (E. coli: 187.8 ± 27.5 MFI vs 201.8 ± 13.7 MFI, respectively; PMA: 519 ± 21.2 
MFI vs 515 ± 140 MFI, respectively) (Fig. 22A-B). One hour after IVIg, the E. coli-induced ROS production 
remains unchanged (from 187.8 ± 27.5 MFI to 181.6 ± 41.3 MFI, p ns) as well as that PMA-induced (from 519 




4.17 MONOCYTES AND PMN PHAGOCYTOSIS IN XLA PATIENTS 
We evaluated in XLA patients the phagocytosis using FITC-labeled opsonized E. coli with the aim to test the 
ability of monocytes and PMN to internalize bacteria through FcγRs. Our results show that monocytes from 
XLA patients perform a normal phagocytosis compared to HD (XLA: 418.7 ± 13.9 MFI vs HD: 430.8 ± 116.6 
MFI) (Fig. 23A). One hour after IVIg, phagocytosis ability decreased (from 418.7 ± 13.9 MFI to 318.2 ± 13.3 
MFI, p 0.043) (Fig. 23A) as previously seen in CVID. Supporting the strong dependence of oxidative burst 
from phagocytosis process, we found a positive correlation between oxidative burst and phagocytosis 
Figure 22. PMN oxidative burst in XLA patients and HD. The PMNs intracellular production of superoxide anions and 
hydrogen peroxide was tested by using the fluorescence probes DHR 123 incubating whole blood samples in a water 
bath at 37°C with opsonized E. coli (1-2x109/ml) and PMA (1.62mM). XLA patients show a comparable PMN E. coli-
induced (plot A) and PMA-induced (plot B) oxidative burst to HD. After IVIg, PMNs ROS production remain unaltered. 




performed by monocytes both before and after IVIg infusion (p=0.027, R 0.862; p=0.043, R 0.824, 
respectively) (Fig 24 A-B).  
Regards the phagocytic activity of PMN we observed that also PMN from XLA perform a normal phagocytosis 
via FcγR compared to HD (XLA: 490.7 ± 80.5 MFI vs HD: 587.3 ± 155 MFI) (Fig. 23B) and that after IVIg infusion, 
phagocytosis remain unaltered (from 490.7 ± 80.5 MFI to 469.5 ± 70.4 MFI) (Fig. 23B) demonstrating that, 
as previously shown in CVID , also in XLA patients IVIg infused a replacement dosage did not affect the ability 











Figure 23. Monocytes and PMN phagocytosis in XLA patients and HD. The quantitative determination of leukocyte 
phagocytosis was tested by incubating whole blood samples in a water bath for 10 min at 37°C with FITC-labeled E. 
coli (2x109/ml). The percentage of cells having performed phagocytosis (granulocytes and monocytes) was analyzed 
as number of ingested bacteria and results are expressed as Mean Fluorescence Intensity. XLA patients show a similar 
monocyte (plot A) and PMN (plot B) phagocytosis compared to HD. After IVIg administration monocytes phagocytosis 
decreased (▪p 0.043), while it remains unchanged in PMN. Results are expressed as Mean Fluorescence Intensity. 
Histograms denote mean values and bars standard deviation. Statistical significance, determined by the nonparametric 






4.18 CALCIUM CHELATION ASSAY ON MONOCYTES  
In order to verify the importance of Ca2+ mobilization in oxidative burst and phagocytosis process in XLA 
patients, we pre-treated whole blood samples with calcium chelator BAPTA-AM. We observed a lower 
reduction of E. coli-induced oxidative burst on monocytes from XLA compared to HD ( p=0.003), indeed the 
average reduction in monocytes from XLA it is about 50% (from 176.5 ± 33.6 MFI to 79.8 ± 19 MFI, p= 0.02) 
and about 75% in monocytes from HD (from 185.2 ± 40 MFI to 46.2 ± 4 MFI, p= 0.01) (Fig. 24A-C) suggesting 
that in XLA patients the role of calcium mobilization for the ROS production is less essential respect to HD. 
On the contrary, the calcium chelation did not affect the oxidative burst induced by PMA (HD: from 350.1 ± 
50 MFI to 342.5 ± 35.3 MFI, p ns; XLA: from 375.8 ± 30.2 MFI to 345 ± 25.3 MFI, p ns) (Fig. 24 D-F), since it is 
able to directly bind PKC and so inducing the oxidative burst bypassing the FcγR engagement, BTK activation 
and Ca2+ mobilization.  
In parallel, to verify the independence of phagocytosis from Ca2+ mobilization, we tested the phagocytic 
ability of monocytes pre-treating whole blood with BAPTA-AM. We observed a regular phagocytosis both in 
XLA patients and HD (XLA: from 418.7 ± 13.9 MFI to 400 ± 15.2 MFI; HD: from 430.8 ± 116.6 MFI to 415 ± 
Figure 24. Correlation between monocytes oxidative burst and phagocytosis before IVIg infusion. Plot A and plot B 
denote a positive correlation between monocytes oxidative burst and phagocytosis before (p 0.027, R 0.862) and after 




109.9 MFI,) confirming that, unlike the ROS production, calcium mobilization is not required for the 
phagocytic process (Fig. 25A-B) 
 
 
Figure 25 Monocytes oxidative burst – Ca2+ chelation. Whole blood samples were pre-treated with 100 μM of 
the calcium chelator BAPTA-AM for 30 min and incubated in a water bath for 20 min at 37°C with opsonized E. 
coli (1-2x109/ml) and PMA (1.62 mM). The conversion of DHR 123 to R 123 was used to evaluate the intracellular 
ROS production. FSC and SSC characteristics were used to identify the monocytes population. The reduction of 
E. coli-induced oxidative burst was lower in XLA than HD (plot A) (▪p=0.003) An average reduction of 75% E. coli-
induced oxidative burst from HD (▪p=0.01) and of 50% from XLA patients (▪p=0.02) was observed (plot A), while 
BAPTA-AM did not affect the oxidative burst induced by PMA both HD and XLA patients (plot D). Results are 
expressed as Mean Fluorescence Intensity. Histograms denote mean values and bars standard deviation. 
Statistical significance, indicated as p value, was determined by the nonparametric Mann-Whitney test and 
Wilcoxon Signed Rank test. Plot B and C show monocytes E. coli-induced oxidative burst in representative HD 
and XLA patient, black peak BAPTA-AM(-) and gray peak BAPTA-AM(+). Plot E and F show monocytes PMA-
















4.19 CALCIUM CHELATION ASSAY ON PMN 
The role of Ca2+ mobilization in ROS production and phagocytosis was also evaluated on PMN from XLA 
patients by pre-treating whole blood samples with BAPTA-AM. Similarly to monocytes, we observed a 
reduction of E. coli-induced oxidative burst on PMN from HD and XLA patients (HD: from 201.8 ± 13.7 MFI 
to 50.4 ± 3.7 MFI, p= 0.01; XLA: from 187.8 ± 27.5 MFI to 90.2 ± 15.4 MFI, p= 0.02) (Fig. 26A-C). Also on PMN 
we observed a greater reduction in HD respect the XLA patients (p= 0.003). On the contrary, providing the 
PMA as a stimulus, the oxidative burst is not affected (HD: from 515.1 ± 140 MFI to 500 ± 80.3 MFI; XLA: 
from 519 ± 21.2 MFI to 499 ± 22.3 MFI) (Fig. 26D-F), since PMA induces the process after direct binding to 
PKC. Confirming the independence from Ca2+ mobilization of phagocytic process, we found similar values of 
phagocytosis before and after incubation with BAPTA-AM both in XLA patients than in HD (XLA: from 490.7 
± 80.5 MFI to 485.4 ± 75.2 MFI, p ns; HD: from 587.3 ± 155 MFI to 578 ± 135.4 MFI) (Fig. 27A-B). 
Figure 26 BAPTA pre-treated monocytes phagocytosis in XLA patients and HD . A 
regular phagocytosis was observed on monocytes (plot A) pre-treating whole blood 
samples with 100 μM of calcium chelator BAPTA-AM. In plot B is show monocytes 
phagocytosis of representative XLA patient, black peak BAPTA-AM(-) and gray peak 
BAPTA-AM(+).  Results are expressed as Mean Fluorescence Intensity. Histograms 







Figure 27. PMN oxidative burst – Ca2+ chelation. Whole blood samples were pre-treated with 100 μM of the calcium 
chelator BAPTA-AM for 30 min and incubated in a water bath for 20 min at 37°C with opsonized E. coli (1-2x109/ml) 
and PMA (1.62 mM). The conversion of DHR 123 to R 123 was used to evaluate the intracellular ROS production. FSC 
and SSC characteristics were used to identify the PMN population. Also in PMN the reduction of E. coli-induced 
oxidative burst was lower in XLA than HD (plot A) (▪p=0.003). An average reduction of 75% E. coli-induced oxidative 
burst from HD (▪p=0.01) and of 50% from XLA patients (▪p=0.02) was observed (plot A), while BAPTA-AM did not 
affect the oxidative burst induced by PMA both HD and XLA patients (plot D). Results are expressed as Mean 
Fluorescence Intensity. Histograms denote mean values and bars standard deviation. Statistical significance, 
indicated as p value, was determined by the nonparametric Mann-Whitney test and Wilcoxon Signed Rank test. Plot 
B and C show PMN E. coli-induced oxidative burst in representative HD and XLA patient, black peak BAPTA-AM(-) 
and gray peak BAPTA-AM(+). Plot E and F show PMN PMA-induced oxidative burst in representative HD and XLA 








Figure 28 BAPTA pre-treated PMN phagocytosis in XLA patients and HD. A regular 
phagocytosis was observed on PMN (plot A) pre-treating whole blood samples 
with 100 μM of calcium chelator BAPTA-AM. In plot B is show PMN phagocytosis 
of representative XLA patient, black peak BAPTA-AM(-) and gray peak BAPTA-
AM(+). Results are expressed as Mean Fluorescence Intensity. Histograms 
















In 2010, a study from Ziegler-Heitbrock L. et al. pointed the attention on a new classification and 
nomenclature of human monocyte subsets [126]. It distinguished classical and non-classical monocytes and 
it introduced a new subset called intermediate monocytes. Before this classification, intermediate 
monocytes were not considered as an individual subset because of its low number and transitional nature. 
Recent studies through gene expression profiling confirmed the unique nature of intermediate human 
monocytes [128]. Recently, clinical studies demonstrated an expansion of these cells in several inflammatory 
and autoimmune diseases like asthma, rheumatoid arthritis and HIV infection [145].  Several studies showed 
intermediate monocyte subset as the main producer of TNF-α and other pro-inflammatory cytokines 
[128,133,144]. Moreover, in CVID patients the expansion of CD14bright CD16+ monocytes were associated 
with T cell activation [224]. For these reasons, intermediate monocytes are now often called pro-
inflammatory monocytes. CVID is characterized by multiple abnormalities in the immune system beyond 
humoral immunity involving dendritic cells (DCs), CD8 T cells, CD4 T cells, invariant natural killer T (iNKT) cells 
and regulatory T cells (Tregs) [225–227]. We demonstrated that CVID patients displayed an increased 
frequency of pro-inflammatory intermediate monocytes (CD14++CD16+). Interestingly, in line with our 
observation on CVID, also XLA patients show an increased percentage of intermediate monocyte, in 
agreement with their underlying inflammatory condition. This observation suggests that a greater frequency 
of intermediate monocytes could be a feature shared between different PAD. On the contrary we found an 
increased expression of CD11b and Siglec 9 only on classical monocytes from CVID patients while monocytes 
from XLA patients showed a normal phenotype, suggesting that the overexpression of these receptors can 
be a peculiar characteristic of CVID and possibly not verifiable in others PADs. CD11b is a component of the 
phagocytic receptor αMβ2 (CD11b/CD18) [228] that plays an important role in phagocytosis process [206]. 
Its overexpression on classical monocytes is probably  caused by a continuous chronic stimulation 
considering the inflammatory status of CVID patients, even if further investigations are necessary, while 
Siglec 9, a member of transmembrane sialic acid-binding proteins CD33-related [209,210] has a postulated 
inhibitory activity on the immune response through host and bacterial sialoglycans recognition [221,222]; 
therefore although CD11b and Siglec 9 have different biological activities, our hypothesis is that the 
simultaneous overexpression of both receptors is a system to respond to infections and to avoid an excess 
of immune response. However, differently from a previous study [229] our results show that the functionality 




observation were also confirmed in XLA patients. This discrepancy from the previous study might be mainly 
due to the different stimuli used for the induction of oxidative burst, in that Aukrust et al [229] used non-
opsonized zymosan acting via TLR2 [230] and PMA, while we used a physiological stimulus, the opsonized E. 
coli that acting via FcγRs [231].  
Our observations clearly indicate that the monocyte compartment is not affected by the immune 
abnormalities of CVID patients and that in XLA patients the lack of a functional BTK did not affect the ROS 
production as well the phagocytic process. Conversely, it remains possible that the expansion of the 
intermediate subset may contribute to the inflammatory status of patients.  
The effect of IVIg on innate immunity cells, it has been mainly analyzed by in vitro models providing 
conflicting results [197,202,232]. A recent study [194] has evaluated the in vivo effect of IVIg on classical and 
non-classical monocytes of patients affected by CVID showing a reduction in the number of non-classical 
CD14+CD16++ monocytes and a concomitant decrease of TNF-α, after 4h from IVIg administration. Therefore, 
we studied the in vivo effect of IVIg replacement, taking into consideration the most recent classification of 
monocytes. We observed in CVID patients an average reduction of about 23% of the total monocyte 
population immediately after IVIg infusion but, more importantly, this reduction was not equally distributed 
among the three monocytes subsets but it involved mainly the intermediate monocytes. in line with the 
observations made on CVID patients, we reported in XLA patients  a prompt reduction of intermediate subset 
after IVIg infusion. This seems to confirm the normalizing effect of IVIg infusion on monocytes distribution 
among the different subpopulations. The reduction of the pro-inflammatory monocytes might be a 
mechanism through which IVIg infusion exert an anti-inflammatory effect, even when infused at replacement 
dosages. The mechanism by which IVIg are able to reduce the intermediate subset remains unclear although 
it is possible that the apoptotic process is involved. It was hypothesized that anti-Fas antibody-mediated Fas 
(CD95/APO-1) ligation and activation of caspases may be involved in that IVIg preparations contain agonistic 
and antagonistic anti-CD95 antibodies.  These antibodies might interact with CD16+ monocytes that 
constitutively up-regulated pro-apoptotic genes making these cells particularly susceptible for apoptotic 
death [194, 233]. 
In addition, we found that IVIg induced a reduction of the expression of CD11b and Siglec 9 in CVID patients 
but exclusively on the monocytes subsets that overexpress them, suggesting that IVIg could have a 
"normalizing" effect only when the surface receptor are overexpressed while IVIGs do not affect the receptor 




9 was possibly due to the binding of antibodies contained in IVIg preparations and Siglec 9 by a specific 
interaction [198,234]. These naturally occurring autoantibodies might contribute to the anti-inflammatory 
effects of IVIg via cell death regulation. All these effects could be an explanation for the anti-inflammatory 
effect that IVIg exert and for which is not known a univocal explanation. It is therefore possible that IVIg exert 
an anti-inflammatory effect by modulating the function of monocytes, an hypothesis corroborated by the 
slight reduction of the phagocytic capacity and oxidative burst observed in CVID and XLA patients after the 
infusion. A possible explanation for the reduction of ROS production by monocytes after the infusion is 
probably related to the reduced phagocytosis ability. It is possible that IVIg may transiently bind the Fc 
receptors on monocytes’ surface and so limiting their availability to the bind with opsonized E. coli. In this 
way, IVIg administrated at replacement dosage might exert a dampening effect on monocytes compartment 
by reducing their fundamental functions. The anti-inflammatory role of IVIg exerted on monocytes was also 
showed by Siedlar et al [194] while other studies showed that the positive role of IVIg in CVID was due to a 
modulation of cellular functions of B cells, T cells, and dendritic cells [184,235-238]. Nevertheless, we 
observed that intravenous IgG administration did not affect the monocytes' functional ability to respond to 
a bacterial stimulation through FcγR, in terms of receptors expression, also confirming that in these 
processes the BTK kinase activity is not involved or more probably, it is bypassed by other redundant 
pathways. Although the oxidative burst and phagocytosis were reduced  after IVIg infusion,  they remain 
within the normal range, suggesting that IVIg do not severely affect the ability to appropriately respond to 
pathogens. 
With the aim to bring to light the possible variation of PMN phenotypes in CVID and XLA patients, we 
analyzed a pool of receptors involved in their activation and cellular responses. Recognition and adhesion of 
serum-opsonized bacteria to human neutrophils were reported to be mediated by the binding of C3b and 
iC3b to specific CRs, including the integrins CD11b/CD18 (CR3) and CD11c/CD18 (CR4) [251-254]. Differently 
from what previously seen on monocytes,  we found that the expression of all receptors analyzed was similar 
in CVID and XLA patients compared to HD, with the exception of an overexpression  in XLA patients of CD66b, 
known as a granulocyte activation marker. This might indicate that in XLA patients PMNs have an altered 
activation status. Further investigations are necessary to clarify if the absence of BTK could induce an altered 
PMNs’ responses to pathogens.  Differently from that observed at resting state [239], E. coli stimulation 
induced a similar up-regulation of CD11c, CD66b, CD16 Siglec 9 expression in CVID, XLA and HD, 




is unaltered and that the BTK kinase activity is not involved in this process or it is bypassed by other 
redundant pathways. In line with that observed in previous study [223] we found a similar reduced 
expression of CD181, the receptor of IL-8, after stimulation with E. coli. It is possible that the proteolytic 
degradation might be responsible for the down-regulation of CD181 after phagocytosis [223]. However, we 
observed that  E. coli stimulation induced a stronger CD11b up-regulation in CVID than HD (especially 
noticeable in eight patients, even if no clinical correlation was found). The wide heterogeneity of this results 
did not surprise considering that CVID encompasses a group of heterogeneous disorders. In fact, the number 
of potential distinct entities within CVID is high [10]. The clinical and immunological heterogeneity might also 
explain the different results obtained in our study and the results published by Casulli et al who showed a 
low CD11b expression on PMN at resting state in CVID [239]. In addition, a considerable variability in the 
CD11b expression in leukocytes exists also among healthy donors [240]. Therefore, it might be important to 
analyze the expression of this receptor in larger populations. Moreover, the procedure used for PMN 
isolation might also induce a more variable expression of certain receptors [203-205]. With the aim to 
understand how the isolation procedure can affect the expression of surface receptors of PMNs, in a 
subgroup of CVID patients we repeated the analysis of the expression of CD16, CD11b and Siglec 9 on isolated 
PMN. While Siglec 9 and CD16 expression was similar on PMN from whole blood and on isolated PMN, the 
expression of CD11b was greatly increased on isolated PMN, showing the importance of the technique used. 
However, we confirmed that there were no significant differences between healthy donors and CVID.  
Similarly to what observed by Kutukculer et al. in CVID pediatric population [241], we showed a normal E. 
coli-induced oxidative burst performed by PMN from CVID patients and this result was also confirmed in XLA 
patients. On the contrary, in CVID the oxidative burst was increased when induced by PMA. This difference 
might depend by the mechanism of action of these stimuli. While opsonized E. coli engage the phagocytosis 
through Fc receptors, in a multi-step process that comprises the formation of phagosome [242,243], PMA is 
a chemical activator of oxidative burst used with the aim to minimize the effect of potential differences on 
the surface receptor status among individuals [240]. Indeed, PMA is able to permeate through the plasma 
membrane and to interact directly with protein kinase C (PKC) by inducing the ROS production [244,245] and 
thus by reproducing the overall activity of respiratory burst [240]. Our results suggest that PMN from CVID 
patients are capable to perform a normal oxidative burst when it is triggered by phagocytosis but when the 
phagocytic step is avoided the oxidative burst is enhanced. As also shown by Casulli et al [239] if PMN were 




the ROS production was reduced. Therefore, it appears that different stimuli activate different PMN 
pathways resulting in different ROS production.  
Currently, the effects of IVIg on PMN from CVID patients has not been fully elucidated [193,226] and the few 
published studies were mainly conducted in vitro. Different mechanisms, such as inhibition of the 
complement cascade, modulation of cytokine production, neutralization of autoantibodies and the 
modulation of inhibitory FcγR expression have been suggested as mechanism responsible for the anti-
inflammatory activity of IVIg administered at high dosages [246]. Several theories have been postulated on 
the mechanisms through which IVIg preparations exert their immunoregulatory properties at replacement 
dosages and different studies proposed an involvement of different type of cells. Some studies demonstrated 
that natural anti-Siglec 9 autoantibodies present in IVIg might lead to a neutrophil apoptosis that is enhanced 
by pro-inflammatory cytokines [234,247,248]. Others studies indicated that IVIg are capable to inhibit PMN 
degranulation [202] and to decrease their pro-inflammatory activity [201]. Higurashi et al [196] showed that 
IVIg trigger in vitro ROS production by neutrophils primed with TNF-α and Teeling et al [197] showed that 
IVIg could induce in vitro neutrophils degranulation even if with a wide variability between different donors. 
Moreover, Casulli et al [193] showed an increased CD11b/CD18 expression and an enhanced ROS production 
when PMN from healthy donors were incubated in vitro with IVIg at low dosages (1–5 mg/ml), a 
concentration similar to that reached after IVIg administration in CVID patients in vivo. Some evidence 
brought to light that the PMN isolation step might induce the expression of surface molecules undetectable 
in whole blood that it might interfere with PMN function [249] and it might alter cellular interactions 
necessary to preserve PMN viability [250].  
Our results suggest that IVIg might exert an anti-inflammatory effect at replacement dosages by acting on 
the monocyte compartment but probably not on PMN. Indeed, in this study we found that the results on the 
effects of IVIg effects on monocytes are not replicated on PMN. We showed that IVIg did not affect the 
receptors expression on PMN in all experimental condition used with the exception of CD181 that decrease 
after IVIg infusion in CVID patients. Actually, a lower expression of CD181 could result in a lower 
responsiveness of PMNs to IL-8. Considering that IL-8 is a chemoattractant for neutrophils, and that it can to 
induce phagocytosis and oxidative burst, it is possible that the reduction of its expression induced by IVIg 
may contribute to an anti-inflammatory effect that infusions of immunoglobulins exert a replacement 




recapitulate the in vivo phenomenon since many cellular and mediator interactions are lacking in the in vitro 
assays.   
Moreover we found that the PMNs’ intensity of oxidative burst after IVIg infusion overlapped that observed 
before infusion in CVID and XLA patients. This ability to perform regular oxidative burst after IVIg when E.coli 
is provided as a stimulus is also reflected by the fact that we found a regular phagocytosis even after the 
infusion. The finding that only on PMNs from CVID patients the IVIg infusion reduce the oxidative burst when 
triggered by PMA is in line with the previous observations that suggest a normalizing effect of 
immunoglobulins infusion only when a cell phenotype or function are altered.  Although our results show 
that PMN from CVID and XLA  patients under treatment with immunoglobulin for several years have a normal 
phenotype and function, further investigations are necessary to verify the PMN receptor expression and 
functionality in naïve untreated patients and to better understand the mechanisms underlying the different 
ROS production according to the stimuli provided. 
The study of the oxidative burst and phagocytosis performed in XLA patients provided us important 
information regard the killing ability of innate immune cells in these patients and prompted us to further 
investigate the role of BTK in these functions. The oxidative burst is a crucial reaction performed by innate 
immune cells needed to degrade internalized particles and bacteria; it is a process dependent from Ca2+ 
mobilization that is the main event downstream BTK activation, BTK is able to activate PLCγ2 which generates 
DAG and IP3 that trigger the release of Ca2+ from endoplasmic reticulum [255] (Fig. 28). Interestingly, our 
results show that the respiratory burst induced through FcγRs in XLA patients is preserved both on 
monocytes and on PMN, suggesting that BTK is not essential for calcium mobilization and consequently for 
the ROS production. Our observations are supported by others studies that reported different pathways for 
Ca2+ mobilization [262-264]. Surprisingly, we found that BAPTA-AM exerted a greater inhibition of oxidative 
burst in HD than XLA, suggesting that oxidative burst in XLA patients appear less dependent from Ca2+ 
mobilization compared to HD. Our hypothesis is that the residual ability to produce ROS, following 
stimulation through FcγR, observed in patients, is probably due to a greater efficacy of Ca2+ independent 
stimulation of PKC, indeed PKC is normally maintained in an inactive conformation [256-258] and it can be 
activated both by DAG, produced by PLCγ2, and by Ca2+ [259] (Fig. 28).  A support to our idea comes from 
the observation that BAPTA-AM did not affect the ROS production when PMA was provided as stimulus. In 
fact, phorbol esters are able to bind the same site of DAG in PKC and are able to induce its activation [260, 




hypothesized that the lack of BTK kinase activity within a whole organism could have limited effects on the 
FcγR-mediated processes.  
In agreement with Ren et al [112], we found that the phagocytosis process performed by monocytes and 
PMN was fully functional, suggesting that BTK kinase activity (and the downstream Ca2+ mobilization) is not 
required for phagocytosis. Indeed, consistent with previous studies [265-268] we observed that the 
phagocytic process remains unaltered in PMN and monocytes pre-treated with the Ca2+ chelator BAPTA-AM, 
supporting the independence of phagocytosis from Ca2+ mobilization. Our results observed in XLA patients  
 
Figure 28 Schematic representation of signaling pathways for phagocytosis and oxidative burst. As a result of FcγR 
clustering, two separate pathways lead to phagocytosis, through a calcium independent way, or to the oxidative 
burst in a calcium dependent manner. Syk induce the activation of Vav and the downstream signaling that lead to 
the phagocytosis process. The main pathway for the activation of the oxidative burst consist in the activation of BTK 
by Syk and the consequent phosphorylation of PLCγ2. PLCγ2 activated produce DAG and IP3 from PIP3. DAG directly 
activate PKC while IP3 bind IP3R on endoplasmic reticulum inducing Ca2+ mobilization that lead to PKC activation and 
finally to the oxidative burst. The lack of BTK in XLA patients is effectively bypassed by the direct stimulation of PLCγ2 
by Syk. The inhibition of Ca2+ mobilization by BAPTA-AM strongly reduce the oxidative burst. PMA is able to bind PKC 





confirm also those obtained by Mangla et al. [269] on Xid mice and by Ren et al using in vitro a BTK inhibitor 
[112].   
In conclusion, taken together our results show that XLA and CVID patients had an increased frequency of pro 
inflammatory monocytes and that IVIg infusion are able to reduce their percentage, suggesting the 
hypothesis that the increased percentage of CD14++ CD16+ monocytes is a common characteristic of these 
two primary immunodeficiencies with a different pathogenesis but with a common clinical infectious 
phenotype. In this way it seems that IVIg exert, in these primary immunodeficiencies, a normalizing effect 
on monocyte compartment by reducing the percentage of intermediate monocytes. This effect may 
contribute to the anti-inflammatory effect that IVIg exert also at replacement dosages. Actually, our results 
seem to show that IVIg infusion exert a damping effect on the overall activity of circulating innate immune 
cells and in particular on monocytes, even if the process analyzed remained fully functional. Finally, the study 
of calcium chelation suggest that in XLA patients exists redundant pathways that bypass the lack of BTK, but 
that also exist in XLA patients efficacy Ca2+ independent pathways for the oxidative burst induced by FcγR 
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Supplementary table 1 Demographic and clinical data of patients CVID *Serum IgG values refer to pre-
infusion levels. F, Female; M, male. COPD: Chronic obstructive pulmonary disease. 
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Supplementary Figure 1. Identification of PMN population. Peripheral blood samples were lysed for 20 min at room 
temperature and washed twice. White cells were suspended in ice-cold PBS and stained at 4 °C for 30 min with CD14 
antibody. Samples were washed, suspended in ice-cold PBS and analyzed by flow cytometry. PMN were identified 
by SSC characteristics and CD14 negative in order to exclude monocytes. A representative healthy donor (plot A–B) 
and a representative CVID patient (plot C–D) are shown. CD15 antibody was used as a specific marker of neutrophils: 
a representative healthy donor (plot E–F) and a representative CVID (plot G–H) are shown. 
Supplementary table 2. Demographic and clinical data of patients XLA *Serum IgG, IgA and IgG values refer to pre-
infusion levels. M, male. COPD: Chronic obstructive pulmonary disease. 
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Supplementary figure 2. Identification of monocyte subpopulations. Peripheral blood samples lysed for 20 minutes at 
room temperature and washed twice. White cells were suspended in ice-cold PBS and stained at 4°C for 30 min with 
CD14 and CD16 fluorochrome-labeled antibodies. Samples were washed, suspended in ice cold PBS and analyzed by a 
4-color flow cytometry single platform. Monocytes subpopulations were phenotypically classified according to their 
expression of CD14 and CD16 into classical (CD14++CD16-), intermediate (CD14++CD16+) and non-classical monocytes 
(CD14+CD16++) in a representative HD (plot A-B) and in a representative XLA patient before and after IVIg infusion (plot 
C-E). Percentages denote mean values. 
Supplementary figure 3. Identification of PMN population in XLA patient. Peripheral blood samples were lysed for 20 
minutes at room temperature and washed twice. White cells were suspended in ice-cold PBS and stained at 4°C for 
30 min with CD15 fluorochrome-labeled antibody. Samples were washed, suspended in ice-cold PBS and analyzed 
by flow cytometry. PMN were identified by Side Scatter (SSC) and CD15 fluorochrome-labeled antibody. CD15 was 
used as a specific marker of neutrophils. A representative XLA patient is shown (plot A-B). 
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